top of page

Search Results

iStock-1223350115 copy.jpg

Search Results

Search this site

62 results found with an empty search

  • New Poll of Midterm Voters Shows Overwhelming, Bipartisan Support for Passage of the ASAP Act (H.R.6130 / S.3267) This Year

    With strong public support and significant momentum, Congress has an opportunity to ensure Medicare policy keeps pace with rapidly advancing Alzheimer’s science WASHINGTON, D.C. – A new poll of 2026 midterm voters reveals overwhelming, bipartisan support for passing the Alzheimer’s Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), legislation that would expand access to innovative tools for earlier Alzheimer’s detection. The findings also underscore strong public support for making Alzheimer’s disease a national priority and demonstrate that voters want Congress to act during the lame duck session. Lake Research Partners and The Tarrance Group surveyed 1,196 registered voters who cast ballots in the 2026 elections and found strong support for Alzheimer’s legislative solutions: Nearly nine in ten voters (89%) support the Alzheimer’s Screening and Prevention (ASAP) Act, with 76% strongly supporting the legislation. Support for the ASAP Act is broad across the political spectrum, with 95% of Democrats, 87% of independents, and 83% of Republicans expressing support. 70% say it is important for Congress to prioritize passing the ASAP Act during the lame-duck session, including nearly 36% who say it is very important. This urgency is shared across party lines. Majorities of Democrats (79%), independents (68%), and Republicans (62%) say passing the legislation this year should be a priority. Notably, nearly half of Democrats (44%) and independents (47%) say it is very important for Congress to act before the end of the year. More than three-quarters of voters (77%) say fighting Alzheimer’s should be a national priority. “These findings reinforce that addressing Alzheimer’s disease is not a partisan issue. Voters across the political spectrum recognize the devastating impact this disease has on millions of American families and want to see meaningful action,” said Ken Thorpe, Honorary Chair of PFCD. “Congress has already demonstrated important leadership in advancing solutions to improve Alzheimer’s detection and care. Now is the time to build on that momentum and get the ASAP Act across the finish line.” As scientific innovation continues to expand opportunities for earlier identification of Alzheimer's disease, it is critical that policies keep pace to ensure timely patient access to breakthrough tools. The ASAP Act would establish a pathway for Medicare coverage of FDA-cleared blood tests for early Alzheimer’s screening through an evidence-based process. The legislation has already garnered significant momentum on Capitol Hill and across the patient advocacy community. The ASAP Act has secured over 235 cosponsors in the House and nearly 60 cosponsors in the Senate, reflecting broad, bipartisan support in both chambers. The House Ways and Means Committee also advanced the legislation unanimously in a 40-0 vote. PFCD joined more than 525 organizations in signing a coalition letter, spearheaded by the Alzheimer’s Impact Movement (AIM) and the LEAD Coalition, urging Congress to advance the legislation. With strong bipartisan support from lawmakers, patient advocates, and the public alike, Congress has an opportunity to translate this momentum into meaningful progress for the millions of Americans impacted by Alzheimer’s disease. “Voters have spoken,” said Thorpe. “Across the political spectrum they support early detection, are eager for national action on Alzheimer's, and urge Congress to deliver. The call is bipartisan, broad, and unambiguous. The window to act is now.” Results of the poll can be found HERE. ###

  • CMS Final Rule Threatens Innovation and Future Treatment Options for Patients

    WASHINGTON, D.C. (November 5, 2026) The Partnership to Fight Chronic Disease (PFCD) expressed serious concern today following the Centers for Medicare & Medicaid Services' (CMS) finalization of policies affecting fixed-dose combination (FDC) therapies under the Medicare Drug Price Negotiation Program (CMS-4215-F). By potentially discouraging the development of innovative treatment combinations and more convenient ways to administer medicines, the rule risks limiting future options for millions of Americans living with serious chronic conditions. The stakes are particularly high for cancer patients. More than 600,000 Americans are diagnosed each year with lung cancer, melanoma, kidney, bladder, head and neck, or stomach cancers combined. For patients facing these diagnoses, advances in treatment can mean fewer infusions, less time traveling to medical appointments, reduced treatment burdens, and more time working, caring for family, and living their lives. Innovations that combine therapies or simplify how medicines are administered can improve the patient experience, lighten caregiver burden and potentially lead to better outcomes. "Patients living with cancer and other chronic diseases need access to more treatment options, not fewer," said PFCD Chair Kenneth E. Thorpe. "For someone undergoing cancer treatment, an innovation that reduces hours spent in an infusion center or eliminates repeated trips to the hospital can make an enormous difference. Policies that discourage these advances fail to recognize the real-world challenges patients and families face every day." The impact could extend beyond cancer. Restricting innovation in how treatments are delivered could set a precedent affecting patients with other serious chronic conditions, limiting future options that improve outcomes, reduce treatment burdens, and support quality of life for the millions of Americans living with one or more chronic illnesses. Affordability matters, but lowering drug costs should not come at the expense of innovations that improve patient outcomes and quality of life. PFCD urges CMS and Congress to address the unintended consequences of this policy and protect incentives to develop treatments that are more effective, accessible, and less burdensome for patients. ###

  • Expanding Access to Untested Peptides Raises Patient Safety Concerns

    WASHINGTON, D.C. (October 28, 2026) In response to today's announcement by the U.S. Department of Health and Human Services (HHS) allowing the temporary compounding of certain peptides lacking FDA approval, the Partnership to Fight Chronic Disease (PFCD) issued the following statement: “For millions of Americans managing one or more chronic conditions, access to safe, effective treatments is essential to maintaining their health and quality of life. Medical innovation offers tremendous promise, but expanding access to products without adequate evidence of their safety, quality, and effectiveness can expose patients to unnecessary and poorly understood risks. “People living with chronic conditions often face complex treatment regimens, multiple medications, and heightened vulnerability to adverse effects or drug interactions. The potential for dangerous interactions among FDA-approved prescription medicines and unregulated compounded products puts patients at significant risk. Expanding access to unproven products without sufficient clinical evidence raises serious concerns and in no way confirms that broader availability means a product has been deemed safe and effective. “PFCD urges HHS and FDA to maintain rigorous, science-based safeguards, transparent patient information, and meaningful oversight. Americans deserve access to promising innovations, but not if it compromises the confidence that the treatments they receive have been appropriately evaluated and will not put their health at greater risk. Expanding access should never come at the expense of patient safety or public confidence in the treatments on which Americans rely.” ###

  • Down Under, Access Looks Different: What Australia Taught Me About Access and Affordability

    Australia has some of the lowest drug prices in the developed world. It also has some of the longest waits for new medicines. As Washington debates Most Favored Nation (MFN) pricing, U.S. policy makers must know that this is no coincidence. The Partnership to Fight Chronic Disease recently helped to convene a group of Australian patient advocates at Parliament House in Canberra. The message was clear and heartbreaking: lower prices do not guarantee access. Many medicines unavailable in Australia have been widely available elsewhere for years. PFCD Vice President of Policy & Advocacy Candace DeMatteis heard from advocates deeply concerned about the lack of access to innovation, the decline of stage 3 clinical trials in Australia, and worries that MFN pricing policy in the U.S. may lead to even fewer innovative medicines available in Australia. As one advocate put it, “We’re a country the size of Texas. A company could easily decide not to launch here altogether.” In a recent survey, 84% of drug companies said Australia is becoming a lower priority for launching new medicines because of extremely low prices. If a country's prices don't make launching worthwhile, companies have no commercial reason to launch there and MFN in the U.S. further complicates that decision. Crossing the globe for care Three advocates shared stories about loved ones who left Australia to get treatment in the United States, as the necessary medications were not available in Australia. One had Alzheimer's disease, one had pancreatic cancer, and one had sickle cell disease. While these are three very different diseases, the patients all share the common problem of lacking access to the medicines they need. Their stories reflect a wider problem: Alzheimer's disease: In 2025, Australia's pharmaceutical advisory committee rejected donanemab, a drug that slows the progression of Alzheimer's. The committee said the risks outweighed the benefits, so patients who want it must pay thousands of dollars out of pocket to access it. Donanemab has been available in the U.S. since 2024. Sickle cell disease: The U.S. approved Casgevy, a one-time gene-editing therapy, in December 2023. In clinical trials, roughly 94–97% of patients on Casgevy remained free from pain crises and hospitalizations for at least a year. As of 2025, the manufacturer had not announced plans to launch Casgevy in Australia, likely due to concerns that the country’s drug pricing policies would make a launch financially unviable, despite the therapy’s availability and reimbursement in more than nine other countries. Pancreatic cancer: In 2026, trial results showed that daraxonrasib, a once-daily pill that targets gene mutations in cancerous cells, nearly doubled survival for patients with advanced pancreatic. The FDA opened expanded access to the drug for American patients in May 2026. In Australia, however, access runs through a clinical trial for patients with untreated metastatic disease, and only two patients have been able to access the drug to date. Additionally, these patients waited almost eight weeks from enrollment to starting the drug, a significant delay for such an aggressive disease. Why the wait? A two-step system Australia's Pharmaceutical Benefits Scheme (PBS) is the public insurance program that reimburses medicines so people can afford them. In Australia, access to a medication takes two separate approvals: The medicine is approved as safe and effective. The medicine is separately approved for PBS funding. Step two is where patients get stuck. The numbers are stark: Even after a medicine is approved, patients wait an average of 466 days for PBS funding. On average, Australians wait 3.6 years to access treatments already available overseas. Only 26% of new medicines available in comparable wealthy countries are funded in Australia. A separate report found that only 25% of new medicines launched worldwide over the past decade have been funded in Australia, compared with 46% in the UK and 88% in the U.S. When a medicine isn't on the PBS, patients often pay out of pocket. 43% of Australians prescribed a medicine not listed on the PBS face out-of-pocket costs. The QALY problem Before a medicine can be listed on the PBS, an advisory committee called the PBAC assesses its cost-effectiveness. This is usually reported as the extra cost for each quality-adjusted life year (QALY) gained. A QALY combines the estimated improvement in a patient's length and quality of life into one number, which is then weighed against the treatment's cost. In plain terms, QALYs put a number on a year of life. That number is lower if you are older, have a disability, or live with a chronic illness. This is discriminatory by design, so much so that use of the QALY is already banned from Medicare drug price negotiations under the Inflation Reduction Act. Yet in Australia, they remain central to deciding who gets treatment. Delays are only part of the story. Australia's pricing system risks losing access to new medicines altogether. What this means for the US: MFN warning signs The message from the patient advocates in Australia was clear. Government price controls have a cost. While we debate the unfairness of paying more, they debate the unfairness of having access to less. The tradeoffs are real, significant, and provide proof that we cannot continue to enjoy U.S. innovation and rapid access to it with foreign reference pricing. The U.S. currently has among the fastest access to new medicines in the world, with 88% of new launches funded compared with 25% in Australia. Importing other countries' price controls brings discrimination through the back door. It also risks importing their access and innovation problems longer term. People living with cancers, rare diseases, and other chronic illnesses, who depend on new and innovative therapies, would be the first to lose. The bottom line Behind every statistic from Australia is a patient who waited, paid out of pocket, or got on a plane to access the medications they need. Lower prices on paper mean little if the medicine never arrives. As U.S. policymakers debate MFN, Australia's experience is a warning about what we stand to lose. Learn more about what MFN pricing could mean for the U.S.: fightchronicdiease.org/MFN.

  • PFCD Urges Careful Consideration of the Impact of National Security Policies on Patient Access to Medical Innovation

    October 22, 2026 (WASHINGTON, D.C.) In response to the U.S. Department of the Treasury’s proposed regulations implementing the Comprehensive Outbound Investment National Security (COINS) Act, including new restrictions involving biotechnology, the Partnership to Fight Chronic Disease (PFCD) issued the following statement: “As policymakers consider new restrictions on international investment in biotechnology, they must also recognize what is at stake for millions of Americans living with one or more chronic conditions who depend on continued medical innovation and access to effective treatments. “Medical innovation is increasingly global. Scientific discovery, clinical research, investment, and drug development often cross national borders, and patients benefit when promising advances can reach them regardless of where those advances originate. Policies that broadly restrict biotechnology investment without adequately distinguishing between transactions that pose genuine national security risks and those that support new treatments risk creating barriers to the development and availability of medicines. “For the 194 million Americans managing one or more chronic conditions, including those with limited or no treatment options, delays in medical progress have real consequences. Patients living with cancer, autoimmune disorders, rare diseases, and other serious chronic conditions already face significant challenges accessing the care they need. Affordability, insurance coverage restrictions, treatment delays, and limited therapeutic options create enormous burdens for patients and their families. Restrictions on investment that supports the development of promising therapies could ultimately reduce treatment choices, slow innovation, and undermine efforts to improve health outcomes. “America’s leadership in biomedical innovation is a strategic national asset worth protecting. As Treasury moves forward with implementing the COINS Act, policymakers should carefully consider evidence-based safeguards that address genuine security risks without unnecessarily disrupting the research, investment, and innovation that patients depend on and that have sustained U.S. biomedical leadership for decades. “National security and patient access should not be competing priorities. We urge Treasury to carefully consider the implications of these proposed restrictions for the millions of Americans living with chronic conditions and to protect American interests while ensuring that patients continue to benefit from the best science and most promising medical discoveries, wherever they originate.” ###

  • GLOBE May Cut Medicare Spending on Paper but Not the Prevalence or Cost Realities of Chronic Disease

    October 1, 2026 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) today expressed serious concern following the Centers for Medicare & Medicaid Services’ (CMS) release of the final rule implementing the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory Medicare payment model affecting certain medicines administered under Medicare Part B. “Americans need relief from high health care costs, but we should not confuse lowering what the government pays for a medicine with lowering the cost of caring for patients,” said Ken Thorpe, honorary Chair of the Partnership to Fight Chronic Disease and professor of health policy at Emory University. “For millions of Americans living with chronic disease, timely access to the right treatment can prevent disease progression, disability, emergency room visits and costly hospitalizations. Any policy that puts that access at risk could create unintended consequences that ultimately increase the burden of chronic disease.” GLOBE uses international drug prices to help determine Medicare payment levels for certain Part B medicines. PFCD has consistently warned that importing foreign pricing policies into Medicare risks importing the access restrictions and treatment delays that patients in other countries can face as well. “For someone living with cancer, an autoimmune disease or another serious chronic condition, a medicine is not simply a line item in the Medicare budget,” Thorpe continued. “It may be what keeps that patient stable, functioning and out of the hospital. Once a physician and patient have found a treatment that works, government policy should not create new financial incentives that could disrupt that care.” PFCD is particularly concerned about the implications of implementing a sweeping, mandatory payment policy through the CMS Innovation Center. A model of this magnitude could affect patients, physicians and the development of future treatments well beyond the immediate savings projected for Medicare. With roughly three in four American adults living with at least one chronic condition, the United States urgently needs policies that address the full cost of chronic disease, not policies that simply shift costs from one part of the health care system to another. “Patients should be the measure of whether health care reform succeeds,” Thorpe said. “If a policy saves Medicare money but makes it harder for patients to get the medicines that keep them healthy, prevent hospitalization or slow the progression of disease, that is not meaningful health care savings.” PFCD urges CMS to closely examine the potential impacts of GLOBE on patient access, continuity of care, physician decision-making and future medical innovation before implementation. Policymakers should instead prioritize reforms that lower patients’ out-of-pocket costs by strengthening prevention and early diagnosis and improving coordinated care for people living with one or more chronic conditions. “America can and should make health care more affordable,” Thorpe concluded. “But we should do it by reducing the enormous human and economic burden of chronic disease, not by making effective treatments harder for patients to access.” ###

  • Thriving Through the Change: Why Menopause, Chronic Disease and Black Women’s Health Belong in the Same Conversation

    For millions of women, midlife brings changes with effects far and wide. Perimenopause and menopause can intersect with cardiovascular disease, diabetes, obesity, bone health and other chronic conditions, all marking an important opportunity to talk about prevention, treatment and what women need to maintain their health and quality of life. Those conversations are especially important for those who face both a disproportionate burden of chronic disease and barriers to accessing high-quality, culturally responsive care. Over the past several years, the Partnership to Fight Chronic Disease (PFCD) has been proud to partner with California State Senator Dr. Akilah Weber Pierson for discussions that address the intersection of a variety of health issues and chronic conditions, particularly those impacting black women. This year “Thriving Through the Change: Menopause, Chronic Disease Risk, and Black Women’s Health,” is a free luncheon seminar at the Southeastern Live Well Center in San Diego that will take place on Monday, September 21. This event will explore the unique experiences of Black women during perimenopause and menopause, including how health care access barriers and social determinants of health affect women during midlife, how chronic diseases can make menopause more challenging, and the importance of culturally relevant health information. Midlife is a critical window for chronic disease prevention and management Menopause is a natural transition, but it occurs at a time when women’s risks for several chronic conditions can change. HealthyWomen notes that declining estrogen during perimenopause is associated with changes affecting cardiovascular health, while metabolic syndrome, which includes risk factors such as high blood pressure, high blood sugar and abnormal cholesterol, is more common after menopause. Heart disease remains the leading cause of death among women in the United States, and Black women face particularly high cardiovascular risk. The disparities extend beyond heart disease. Black women are 90 percent more likely to have diabetes than white women, illustrating why menopause cannot be considered in isolation from the broader chronic disease landscape. Menopause symptoms themselves can also affect everyday health and well-being. As many as 8 in 10 women in midlife experience vasomotor symptoms, such as hot flashes and night sweats, yet only about 1 in 4 receives treatment. Women of color are more likely to report these symptoms and may experience them for longer periods than white women. Sleep disruption associated with these symptoms can diminish quality of life and is linked with conditions including hypertension, diabetes and obesity. Access is part of the health equation Knowing what is happening in your body is important. Being able to do something about it is just as important. Preventing and managing chronic disease requires a health care system that allows women to receive regular primary and preventive care, appropriate screenings and diagnoses, specialty care when necessary, and access to treatments that they and their health care providers determine are appropriate. The Alliance for Women’s Health and Prevention has made that connection central to its work, emphasizing that early and equitable access to screening, diagnosis and preventive interventions can improve women’s health and longevity. Its 2026 policy agenda specifically calls for broad access to routine primary care, culturally competent care, meaningful access to specialty care and new approaches, including telehealth and collaborative care teams, that can improve access in medically underserved communities. For Black women, ensuring that care is both accessible and responsive to their experiences is particularly consequential. The American Heart Association has identified the menopause transition as an important period for cardiovascular health and has highlighted persistent racial disparities in cardiovascular disease among Black women. The goal should not simply be to treat illness once it has progressed. It should be to give women the information, care and treatment options they need to recognize risks earlier, manage existing conditions effectively and make informed decisions with their health care providers. Bringing the conversation into the community “Thriving Through the Change” is designed to help create exactly that kind of dialogue. By bringing together community members, health leaders and policymakers, PFCD and Senator Weber Pierson are creating a space to talk openly about menopause within the broader context of chronic disease, and to make sure the experiences of Black women are part of the discussion.

  • Protecting Patient Access: Why Innovation In How Care Is Delivered Matters

    For many patients, access to treatment is about more than whether a therapy is covered. It is also about what it takes to realistically fit that care into their lives. On July 30, the Partnership to Fight Chronic Disease (PFCD) hosted a Congressional Hill Briefing examining the Centers for Medicare & Medicaid Services’ (CMS) proposed treatment of fixed-dose combination (FDC) therapies under the qualifying single-source drug (QSSD) definition in Medicare’s Drug Price Negotiation Program. The discussion focused on the patient impacts related to how a proposed change could treat two separately FDA-approved products as a single qualifying single-source drug, even when one product contains an additional active ingredient that enables a different route of administration, such as moving from an intravenous infusion to a subcutaneous injection. These kinds of distinctions can have a meaningful impact on patients. More convenient treatment options can reduce the time patients spend traveling to and receiving care, as well as the burden on family members and caregivers. For older adults and people living in rural or underserved communities, reducing these barriers can make a significant difference in their ability to stay on course with prescribed treatment. During the briefing, patient and community advocates shared what these barriers can look like in real life. As PFCD's Vice President of Policy and Advocacy Candace DeMatteis emphasized the importance of policymakers more fully considering the patient experience when evaluating changes to Medicare’s drug negotiation framework. Innovation is not only about developing new medicines; it can also mean finding better ways for patients to receive the treatments they need. Anna Howard of the American Cancer Society Cancer Action Network highlighted the significance of understanding patients as people with lives, responsibilities, and challenges beyond their treatment. For patients living in rural communities, accessing care can mean traveling several hours to reach a cancer treatment facility. When a therapy offers a less burdensome way to receive treatment, that difference matters. Burton Eller of the National Grange shared the story of a rancher in his 60s battling stage three cancer who was driving to Fort Worth three days a week for infusions, a schedule that consumed much of the week for both him and his wife. Stories like these underscore why Medicare policy should account for the real-world impact of how care is delivered. Policies that unintentionally discourage investment in new formulations or routes of administration could limit future treatment options and make it harder for patients to benefit from innovations designed to make care more accessible. PFCD, joined by 50 patient, provider, and health organizations, recently submitted comments to CMS urging the agency to reconsider its proposed approach to FDC therapies. As CMS considers changes to the Medicare Drug Price Negotiation Program, policymakers should ensure that the framework continues to support patient-centered innovation and recognizes the importance of expanding how and where patients can receive care. Read the full comments to CMS from PFCD and 50 other organizations HERE.

  • PFCD and Partners Urge CMS to Protect Patient Access

    The Partnership to Fight Chronic Disease (PFCD), joined by 50 patient, provider, and health organizations, submitted comments urging the Centers for Medicare & Medicaid Services (CMS) to reconsider a proposed change to how fixed-dose combination therapies are classified under the Medicare Drug Price Negotiation Program. The proposal could treat two separately FDA-approved products as a single qualifying single source drug – even when one product includes an additional active ingredient that enables a different route of administration, such as a shift from intravenous infusion to subcutaneous injection. For patients, these distinctions matter. A shorter or more convenient administration method can reduce travel, time away from work or caregiving responsibilities, and other barriers to staying on treatment – particularly for older adults and people living in rural or underserved communities. Medicare policy should recognize the scientific advances and patient benefits associated with therapies that expand where and how care is delivered. Read PFCD’s full letter to CMS here.

  • How a Proposed Rule Could Impact Treatment Options for Patients Living With Chronic Disease

    If you're one of nearly 200 million Americans living with a chronic disease, Medicare policy debates can often feel far removed from your daily life. But sometimes, a technical-sounding proposal can have real consequences for the treatments you rely on — and that's exactly what's happening right now. The Centers for Medicare and Medicaid Services (CMS) is considering a change to how it classifies certain drugs under the Medicare Drug Price Negotiation Program (MDPNP) established under the Inflation Reduction Act. Specifically, the agency is looking at whether an IV infusion and a subcutaneous (under-the-skin) injection of the same medication should be counted as one product — not two – for the purposes of price setting. At first, that might sound like a bureaucratic accounting question. But for patients and caregivers, the stakes are very real. An IV infusion requires patients to travel to an infusion center or hospital outpatient facility, often for appointments lasting several hours. By contrast, a subcutaneous injection can be administered in minutes, typically in a doctor’s office or even at home. Giving patients the choice between treatments – and administration of treatments – is critically important. Injections are often less costly than IV infusions and far more accessible for many populations, including rural patients who may live hours from an infusion center, individuals without reliable transportation, and elderly patients and caregivers. When given the choice, 71% of patients prefer injection over IV administration (for a given therapy) – but this proposal from CMS effectively eliminates that choice for patients – and sends a signal that could discourage further innovation in this space. The implications of this proposed rule extend beyond patient experience. Developing an injectable alternative is not a simple modification—it requires years of research, substantial investment, and a separate FDA review process. The FDA, not CMS, has the scientific expertise and statutory authority to determine whether therapies are distinct medicines. When the FDA approves both an IV and a subcutaneous version as separate products, it does so based on independent evaluation of each formulation’s safety, efficacy, and delivery. Treating them as the same product under Medicare policy disregards these distinctions and the meaningful differences they represent for patients. It also risks exceeding CMS’s regulatory role while undermining FDA determinations. This issue is not about a single therapy or company. It is about the signal this policy sends to researchers and developers about which types of innovation are worth pursuing. Under the proposed rule, CMS would effectively eliminate financial incentives for pharmaceutical companies to develop more convenient, patient-friendly delivery options. If Medicare policy treats an improved delivery method the same as its predecessor, it raises a fundamental question: why invest in making treatments easier and safer for patients if those improvements are not recognized as meaningful advancements? The likely result is that resources will be redirected elsewhere. Over time, this could slow progress on innovations that make chronic disease more manageable. early evidence already suggests that the Inflation Reduction Act has had negative effects on research and development, which this policy could further exacerbate. Your voice matters CMS is accepting public comments on this proposal through August 17. That means patients, caregivers, providers, and advocates have a real opportunity to weigh in before decisions are made. Policymakers need to hear from the people who live these realities every day — not just the technical arguments, but the human ones. What does it mean to you to have a treatment option that fits your life? What would you lose if those options disappeared or stopped being developed? Innovation means finding better ways to deliver treatments with less burden, more flexibility, and greater dignity for the people who need them most. Medicare policy should reflect that. Comments on the Medicare Drug Price Negotiation Program for IPAY 2029 are open through August 17, submit comments here.

  • Rewriting the Script for People Living With Chronic Disease is About Much More Than Just Cost

    May 20, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in advance of this week’s anticipated Senate vote-a-rama on the reconciliation bill: “The Partnership to Fight Chronic Disease urges Congress to carefully consider the unintended consequences that foreign drug pricing policies could have for Americans living with one or more chronic conditions. “Patients living with cancer, Alzheimer’s disease, autoimmune disorders, cardiovascular disease, diabetes, and rare diseases depend on timely access to innovative medicines and individualized treatment options. Policies that tie U.S. drug prices to foreign government-controlled systems risk importing the same delays, coverage restrictions, and rationing practices that limit patient access in other countries. “Many of the countries used as reference points for Most Favored Nation (MFN) pricing proposals routinely restrict access to newer therapies and rely on cost-effectiveness measures, including the use of the quality-adjusted life year, or QALY, that can disadvantage older adults, people with disabilities, and patients with complex chronic conditions. The result is reduced treatment choices and delayed access to therapies that can improve or extend lives. “PFCD is also deeply concerned about the long-term impact these policies could have on medical innovation. Breakthroughs in cancer, cardiovascular disease, obesity, diabetes, rare diseases, and other chronic conditions have transformed patient outcomes and created new hope for millions of families. Importing foreign price controls would weaken the research and development ecosystem that drives future cures and treatment advances. “Americans living with chronic disease deserve policies that improve affordability and strengthen access without sacrificing innovation, physician and patient choice, or future medical progress. Congress should reject foreign pricing policies that risk undermining patient care and instead pursue solutions that address the true drivers of health care costs while preserving access to life-saving treatments.” ###

  • Progress Takes Many Forms When It Comes to Fighting Chronic Conditions Like Alzheimer’s Disease

    April 17, 2026 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to recent analyses related to Alzheimer’s disease. “The recent review of anti-amyloid Alzheimer’s therapies highlights the complexity of measuring progress against a devastating disease, but its conclusions should be viewed with important context. By combining older, unsuccessful therapies with newer treatments that have demonstrated the ability to slow cognitive decline, the analysis risks misrepresenting meaningful advances and diminishing what these medicines can offer patients and families today. “For those living with Alzheimer’s and related dementias, even modest slowing of disease progression, such as the reductions in decline observed in recent trials, can translate into more time with loved ones, greater independence, and a critical window for future breakthroughs. Dismissing these gains because they are not cures overlooks what matters most to patients and caregivers. “At a time when the burden of Alzheimer’s continues to grow, the answer is not to step back from innovation, but to build on it, advancing a range of scientific approaches, improving how we measure meaningful outcomes, and ensuring patients have access to emerging therapies. The Partnership to Fight Chronic Disease remains committed to supporting continued research, thoughtful evaluation of evidence, and policies that accelerate progress for the millions of Americans affected by this disease.” ###

  • New Analysis: Patients Paid the Price When Europe Controlled Drug Costs

    Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient impact, the independent think tank called Europe a "cautionary tale" for the U.S., particularly as the Trump administration continues to champion the expansion of price controls through “Most Favored Nation” (MFN) drug pricing policies. Patient wait times for treatment availability, as measured from regulatory approval to payer coverage, were slower in 25 of the 27 EU nations compared to the U.S. from 2014 to 2022, according to IQVIA. The Galen Institute found that, of 290 new medicines introduced globally between 2011 and 2018, 89% were available in the U.S. compared with only 62% in Germany, 48% in France and Switzerland, and 40% in Ireland. The data were starker for oncology medicines: 96% were available to American patients compared with 73% in Germany, 66% in France, 62% in Switzerland and 51% in Ireland. The report also traced the erosion of the pipelines that deliver patients new therapies. Between 1960 and 1965, European firms produced 65% of all new medicines worldwide. By 2004, that share collapsed to 18% while the U.S. share climbed to 62%. ITIF cited research by University of Southern California health economist Darius Lakdawalla and his colleagues, who found that lowering U.S. drug prices to European levels would reduce life expectancy for adults ages 55 to 59 by roughly two-tenths of a year. That amounts to more than four million life-years lost across that age group alone. For the more than 194 million Americans living with multiple chronic conditions, the analysis of Europe's decline hits close to home. These patients depend on a steady flow of new therapies to manage illness, preserve quality of life and survive. As a recent Partnership to Fight Chronic Disease study explored, chronic conditions are the primary driver  of rising health care spending across Medicare, Medicaid and private insurance, and obesity is a primary culprit. Adding longer wait times for new treatments to an already strained U.S. health care system would delay care, worsen patient outcomes and drive costs higher. The risk is too great. Ultimately, ITIF's analysis is a patient story. Europe's experience shows what happens when governments suppress the returns that fuel innovation. Americans with chronic disease cannot afford for history to be repeated. The full report from ITIF can be found HERE .

  • New Case Study Highlights the Risk of Severe Treatment Delays for U.S. Patients Fighting Cancer Due to MFN

    For millions of Americans living with cancer, access to innovative treatments is urgent and often lifesaving. The U.S. has long led the world in developing cutting-edge therapies, giving patients earlier access to new medicines and contributing to improved survival rates and quality of life. With 345 cancer medicines launched over a twelve-year span compared to just 191 in the U.K., a difference that translates directly into more treatment options and better outcomes for patients, it is clear that preserving that leadership must remain a top priority for policymakers. A new case study  demonstrates how patients with cancer in the U.K. have waited years, sometimes more than a decade, for access to a blood cancer medicine that is widely available in the U.S. This stark contrast highlights how price control policies, such as the Trump administration’s Most Favored Nation (MFN) proposals, which would tie U.S. drug prices to those set by foreign governments, risk undermining the very system that facilitates robust access to the latest treatments available to Americans today. Countries that rely on government-mandated price setting, like the U.K., utilize cost-effectiveness frameworks, such as the quality-adjusted life year (QALY), that systematically serve to delay or deny access to treatments by an arbitrary, and arguably unethical, measure. In this new series of case studies, the Partnership to Fight Chronic Disease will demonstrate how importing such pricing frameworks into the U.S. risks importing those same barriers for American patients and families navigating complex diagnoses. For people living with cancer and other chronic conditions, delays in access and fewer treatment options can have a devastating impact. Learn more about the unintended consequences of MFN at fightchronicdisease.org/MFN .

  • Lowering Health Care Costs and Improving Overall Outcomes Cannot Come at a Cost to Patient Access

    February 25, 2026 (WASHINGTON, D.C.)  — The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the State of the Union address, during which President Trump supported codifying “Most Favored Nation” (MFN) drug pricing: “The 194 million Americans living with multiple chronic conditions depend on consistent, timely access to the therapies that help manage their health. Ensuring these treatments are affordable is a goal PFCD strongly supports, and one that President Trump rightly elevated in his State of the Union address. Codifying MFN into law, however, would fundamentally shift the U.S. toward access delays and gaps observed in the countries that MFN pricing would emulate without any guarantees of improving affordability for patients. “Americans living with complex, chronic conditions cannot afford the disruption and volatility MFN would bring to the U.S.-based innovation ecosystem, jeopardizing access to new therapies for cancer, autoimmune disorders, neurological conditions, and rare diseases. MFN would also import foreign benchmarks that rely on discriminatory cost-effectiveness measures like the quality-adjusted life year (QALY), a metric that systematically undervalues the lives of elderly, disabled and chronically ill patients , and that federal law explicitly prohibits in Medicare. Importing those prices means importing the discriminatory assumptions on which they are built. "The patients most dependent on a stable, innovative therapeutic landscape are also the most vulnerable to the consequences of getting this wrong. PFCD urges Congress to avoid codifying a policy that risks undermining both American values and biomedical innovation. To deliver on President Trump’s desire to improve health care affordability, Congress must instead focus its energy on the insurance companies that stand between patients and their medicines while continuing to drive up premiums, deductibles, and coinsurance. We stand ready to work with policymakers toward affordability solutions that keep patient access, outcomes and medical progress at the center." For more health and policy stakeholder perspectives on MFN, please visit www.fightchronicdisease.org/mfn .

  • PFCD Celebrates Passage of PBM Reforms Critical to Lowering Costs and Improving Outcomes for Americans with Chronic Disease

    February 4, 2026 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) applauds the passage of the Consolidated Appropriations Act of 2026 and its inclusion of many important health care elements that support efforts to better prevent and manage costly chronic conditions. Notably, the bill will increase transparency and lower health care costs for people living with one or more chronic conditions by instituting much needed reforms for pharmacy benefit managers (PBMs) in both Medicare Part D and the commercial market. This represents an important first step toward holding PBMs accountable, protecting patient access, and improving the affordability of prescribed medications. More specifically, the PBM reforms included in this package would: Require Part D plans to contract with any pharmacy that meets reasonable, relevant standard terms, with HHS directed to define and enforce those standards beginning in 2029. Limit PBM compensation in Part D to flat, bona fide service fees, fully delinked from drug prices, formularies, and utilization, while passing through rebates and discounts. Mandate comprehensive PBM reporting in Part D on drug utilization, pricing, rebates, retained compensation, and PBM-owned pharmacy activity starting in 2028. Bar PBM contracts that restrict disclosure or reporting, ensuring access to financial and utilization data across the commercial market. Require regular, drug-level reporting to federal agencies on pricing, compensation, rebates, and benefit designs that steer patients to PBM-affiliated pharmacies for PBMs in the commercial market. Require PBMs serving ERISA plans to pass through 100% of rebates and related payments to the issuer, grant audit rights, and strengthen fee and rebate disclosure. The new law also enables better prevention and early detection of cancer by allowing Medicare to cover cutting-edge multi-cancer diagnostics that can detect multiple cancers from a single blood test. Other important provisions in this legislation that aim to advance the fight against chronic disease focus on improving access to care across Medicare and rural communities, funding research for cancer and Alzheimer’s and supporting mental health services. PFCD stands ready to engage with the Administration as relevant agencies work to implement this legislation. We call upon Congress to continue to pursue bipartisan, patient-centered reforms to PBM and health plan behaviors that inhibit access and affordability for the millions of U.S. individuals and families managing chronic conditions.

  • Medicare Drug Pricing Must Not Create New Barriers for People Living with Chronic Disease

    January 28, 2026 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement of 15 new drugs selected for price-setting in Initial Price Applicability Year (IPAY) 2028: “Prescription medicines are a cornerstone of chronic disease management for Medicare beneficiaries, the vast majority of whom rely on one or more medications every month to maintain their health, independence, and quality of life. As CMS moves forward with the Medicare Drug Price Negotiation Program, it is essential that efforts to lower government costs do not unintentionally restrict beneficiary access to medicines or undermine continued innovation for medicines that treat chronic conditions. “PFCD remains concerned that this program risks creating new barriers to care through increased utilization management practices, overly broad drug definitions, and insufficient safeguards against discriminatory value metrics. The Inflation Reduction Act (IRA) did nothing to address the role of pharmacy benefit managers, and CMS has refused to take action to protect patient access to price-set medicines. Coverage alone does not guarantee access. Step therapy, prior authorization, and formulary restrictions already delay or deny medically appropriate treatment, and the lack of CMS oversight may cause these insurer behaviors to increase as this program continues.   “Further, the IRA flat out ignores clinical realities and threats to innovation. Over the past several years, we have seen the impact that this law has had on the research and development of small molecule medicines, which are essential to the treatment of many chronic diseases and often preferred by seniors for their ease of use and accessibility. The earlier price-setting timeline for small molecule medicines continues to be a significant disincentive for investment. In this round of IPAY drug selection, six of the 15 medicines would not have been eligible had the small molecule penalty of the IRA been fixed. For that reason, we again call for Congress to support and pass the bipartisan EPIC Act ( H.R. 1492 / S.832 ). “PFCD urges CMS to strengthen beneficiary and caregiver engagement, enhance transparency around how patient input informs decision-making, and work proactively to prevent unintended consequences that could limit access, exacerbate disparities, or chill research into unmet medical needs. We stand ready to work with policymakers to ensure Medicare drug pricing policies protect patient access, reflect real-world clinical care, and support a health care system that prioritizes better health outcomes while responsibly managing long-term costs.”

  • Chronic Disease is Straining U.S. Health Care, and Insurers Aren’t Helping

    Chronic conditions are the primary driver of rising U.S. health care spending across Medicare, Medicaid and private insurance, a new study from the Partnership to Fight Chronic Disease (PFCD) detailed last week. Costs are highly concentrated among patients living with three or more chronic conditions, and obesity plays a central role . PFCD Chair Kenneth Thorpe, PhD., and Peter Joski authored the new research report , which is particularly relevant leading up to two House hearings this Thursday. If chronic disease is the cost driver, insurance companies might be the engine. Five CEOs from large insurance companies are scheduled to meet first with the Committee on Energy and Commerce and then the Committee on Ways and Means. The largest U.S. insurance companies have vertically integrated into health care conglomerates that repeatedly prioritize profits over patients. This has led to a system that struggles to deliver timely, affordable treatment to Americans. About 60% of U.S adults live with at least one chronic condition, and 20% have multiple. The study uncovered how increased spending is linked to an increase in the number of patients with multiple chronic conditions, highlighting how per-person plan spending for privately insured patients with three or more chronic conditions rose 31% from 2011 to 2022. These patients comprise 27% of private-insurance patients but nearly 60% of category spending. In 2022, chronic disease accounted for 93% of Medicare spending and 82% of Medicaid spending. Meanwhile, the Centers for Medicare and Medicaid Services (CMS) announced last week that national health expenditures increased by 7.2% in 2024 , following a 7.2% surge in 2023. At $5.3 trillion, health care consumed a staggering 18% share of GDP in 2024. About four in 10 American adults have obesity. Among Medicaid beneficiaries managing four or more chronic conditions, more than half have obesity. The research makes clear that slowing unsustainable spending growth requires preventing the onset and progression of chronic disease, addressing obesity as a chronic illness, and improving care coordination. Meanwhile, many health experts observe an insurance marketplace that appears to be moving in the opposite direction. Rather than support prevention and better disease management, insurers are increasingly focused on maximizing profits through evolving formulary and utilization management practices that consolidate market power and slow access to necessary care. Insurers now own pharmacy benefit managers, provider groups, group purchasing organizations, and health systems. UnitedHealthcare alone operates nearly 2,700 subsidiaries . Insurance decision-making has shifted from patient-centered to business-centered. Utilization management, prior authorization requirements, and formulary restrictions routinely delay or deny medically necessary care. Rather than staying focused on delivering life-altering treatment, physicians are forced to navigate step therapy limitations, insurance denials, and other red tape. This leaves chronic disease patients waiting for approvals while their health deteriorates, ultimately leading to costly medical care and preventable hospitalizations. Congressional lawmakers should consider how current insurance practices are fueling increased costs throughout the health care system by ignoring the patients themselves and how they access the treatments and resources their physician recommends.

  • New Analysis Links Obesity and Multiple Chronic Conditions to Unsustainable Spending Growth Across Insurance Programs

    January 14, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) today released a new research report, “ The Association of Obesity and Chronic Conditions Treated as it Relates to the Growth in Health Care Spending by Source of Insurance, 2011–2022 ,”  by PFCD Chair Kenneth E. Thorpe and Peter J. Joski. The report finds that the increasing prevalence of obesity and multiple chronic conditions is the dominant force behind rising health care spending across Medicare, Medicaid, and private insurance. Health care spending is increasingly concentrated among a small share of patients with complex, obesity-related illnesses. The report highlights that obesity, now affecting four in 10 U.S. adults, plays a central role in this trend. Obesity rates increased across all insurance types and chronic disease categories from 2011 to 2022, coinciding with rapid spending growth among patients managing multiple conditions. Among privately insured individuals with three chronic conditions, per-person spending rose 31% over the study period, while just 27% of patients now account for nearly 60% of private insurance spending. Among Medicaid beneficiaries with 4+ chronic conditions, 51.2% also had obesity. Thorpe’s analysis finds that policy approaches focused on limiting coverage, increasing reimbursement barriers, or imposing blunt price controls do not prevent disease or slow long-term cost growth. Instead, meaningful cost containment requires policies that reduce the burden of chronic disease itself, by preventing onset, slowing progression, and addressing obesity as a root cause across populations and insurance programs. “Our analysis shows that chronic disease, particularly obesity-related conditions, is now the dominant driver of U.S. health care spending growth, with the vast majority of new Medicare and Medicaid dollars going to patients managing multiple chronic conditions. These findings make clear that slowing cost growth will require sustained investments in prevention and better chronic disease management, not blunt price controls, so we can improve outcomes while reducing the long-term cost burden on patients and the health system,” said PFCD’s Ken Thorpe. The full paper can be found HERE , and a related one pager HERE . ### The Partnership to Fight Chronic Disease (PFCD)  is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease.

  • PFCD Statement on Mandatory Medicare Demos Implementing Most Favored Nation Drug Pricing

    December 19, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D: “PFCD remains opposed to a MFN approach to drug price-setting that would import foreign price controls, threaten patient access, pose ethical concerns, stifle U.S. medical innovation, and adopt discriminatory metrics of value, despite federal law prohibiting the use of such metrics in Medicare. The nearly one in three Americans living with two or more chronic conditions rely on timely access to needed therapies. By tying prices to external benchmarks, these MFN models threaten to reduce the availability of key therapies, create sudden shifts in medical coverage, and introduce uncertainty that disrupts long-standing care routines. These effects are especially concerning for individuals who depend on consistent, long-term treatment plans to manage complex conditions. “While such policies claim to be aimed at lowering costs, they ultimately hinder patient-centered care and outcomes for the 130 million Americans with multiple chronic conditions by limiting therapeutic options and delaying access to treatments and care. Instead, policymakers should keep patient access and outcomes at the core of any solutions and focus instead on reining in pharmacy benefit managers and demanding greater transparency around rising premiums, deductibles, and coinsurance. “No matter how appealing the promise, it is not possible to impose foreign price controls and continue to maintain U.S. leadership in innovation and patient access to cutting-edge medical advances.”

  • New Report: Chronic Disease Could Cost the U.S. $47 Trillion Over Next 15 Years

    Multiple Chronic Conditions a Key Driver of Unsustainable Spending Growth December 18, 2025 (Washington, D.C.) New national and state data released today by the Partnership to Fight Chronic Disease (PFCD) projects that chronic disease is on pace to cost the United States as much as $47 trillion between 2024 and 2039, including $2.2 trillion annually in medical costs and nearly $900 billion each year in lost productivity by 2039 . The analysis, conducted by GlobalData, highlights a stark reality: 5% of people account for nearly 50% of total health care spending, driven largely by the growth of patients living with three or more chronic conditions.  By 2039, the combined per-person medical and productivity cost of chronic disease could reach $12,900 per U.S. resident if meaningful action is not taken. However, the data also points to a powerful opportunity. Better prevention, earlier intervention, and improved management of chronic disease, especially obesity, could prevent 150 million new chronic disease cases, save 13.5 million lives, and avoid $7 trillion in costs nationally between 2024 and 2039.  Even modest behavioral changes and improvements in care delivery could save $125 billion per year, while treatment breakthroughs and more optimistic prevention scenarios could generate $465 billion in annual savings. “These findings make clear that chronic disease, and especially the accumulation of multiple chronic conditions, is the main driver of rising health care spending in the United States,” said PFCD Chair Ken Thorpe. “The path to better overall health outcomes, sustainability and productivity runs through prevention, innovation and better coordination of care, not access restrictions that leave patients sicker and costs higher.” Please visit www.fightchronicdisease.org/pfcd-in-the-states for the full set of national and state-level fact sheets and associated methodology. ### The Partnership to Fight Chronic Disease (PFCD)  is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease.

  • PFCD Applauds Senate Action on PBMs

    December 5, 2025 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the introduction of the Pharmacy Benefit Manager (PBM) Price Transparency and Accountability Act:   “The Partnership to Fight Chronic Disease (PFCD) applauds Senate Finance Committee Chairman Mike Crapo and Ranking Member Ron Wyden for introducing the bipartisan Pharmacy Benefit Manager (PBM) Price Transparency and Accountability Act , which aims to fix market distortions and lower prescription drug costs for patients and taxpayers. For the more than 190 million Americans living with one or more chronic conditions, reforms that increase transparency, fairness, and accountability among PBMs are essential to improving access and affordability.   “Efforts to make America healthier require policymakers to address misaligned incentives that allow PBMs to profit while patients face rising premiums, deductibles, and coinsurance at the pharmacy counter. By delinking PBM compensation from list prices and requiring that Medicaid payments flow more directly to pharmacies and dispensing providers, this legislation moves the system closer to one that prioritizes patients over middlemen.   “This legislation’s provisions to strengthen reporting, audit authority, and ‘any willing pharmacy’ contracting will help safeguard independent and rural pharmacies that many people with chronic conditions rely on for timely access to medicines and counseling. These steps, combined with greater oversight of PBM practices across Medicare and Medicaid, reflect the kind of bipartisan, patient-centered solutions PFCD has consistently championed to protect access while addressing affordability.   “Achieving better health outcomes requires a comprehensive approach that pairs prevention with reliable access to evidence-based treatments. Greater transparency when it comes to cost and access for prescribed treatments is essential for people living with chronic conditions and the providers supporting their care. This bill is an important step in that direction, and PFCD urges Congress to swiftly advance this legislation.”

  • Why PBM Reform, not MFN, is a Viable Path to Affordable Drug Access

    More than half of American adults manage multiple chronic conditions . The prevalence is enough to strain the U.S. healthcare system and challenge patient access to new treatments. To compound the issue, pharmacy benefit managers (PBMs) and others siphon nearly half of every dollar spent on brand-name drugs, driving up costs for patients. Reform for how Americans access drugs is a primary topic in Washington. Of the two trending options on the table, only one puts patients first. PBM reform and most favored nation (MFN) pricing have gained significant recent traction. One key distinction is the former directly confronts the issue at hand by mitigating the influence of middlemen, whereas MFN imports drug prices set by foreign governments with a riskier range of potential outcomes. Any solution must prioritize patient access. Today, PBMs wield enormous influence over which medicines patients receive and what they pay. Their rebate-driven models, formulary barriers, and use of affiliated group purchasing organizations (GPOs) often prioritize financial return over clinical need. For people managing chronic disease, these practices can delay effective therapy and inflate out-of-pocket costs. PBM reform seeks to restore patient-centered access by curbing opaque pricing practices and ensuring negotiated savings reach patients. By reducing pricing distortions created by PBMs and increasing transparency, reform targets the systemic barriers that most consistently raise costs for patients. In the interim, direct-to-patient (DTP) programs can offer short-term relief. They allow patients to bypass intermediaries altogether and buy medications directly from manufacturers at a transparent, often significantly discounted, price. For some, especially those with high deductibles, limited coverage or no insurance, DTP would address unpredictability at the pharmacy counter and minimize surprise costs. In time, there could be an opportunity to expand DTP, integrating insurance coverage and enabling broader participation. MFN moves the U.S. in another direction. By tying drug prices to those set in foreign markets, MFN would introduce volatility that would limit patient access to new medicines. By undermining the conditions that support steady development, testing, and rollout of new therapies, MFN would jeopardize access for patients who rely on new therapies to manage complex or rare conditions. The pursuit of parity with other nations can come at the expense of timely care for Americans who need it most. Across Europe and Canada, patients routinely face delayed and constrained access to medicines due to government price-setting practices. In Canada, a 2021 Fraser Institute analysis found newly approved therapies often arrive over a year later  than their U.S. equivalents, shrinking treatment windows for people with chronic disease. In the U.K., rare disease patients are frequently denied access  to transformative treatments when the National Institute for Health and Care Excellence deems them not to be “cost-effective”. It would be precarious to address affordability in the U.S. by treating countries with major access concerns as the rubric. It’s also clear from those experiences that we cannot simply adopt foreign prices and still enjoy U.S.-level access to medicines or have the same pace of innovation. PBM reform provides a clearer path forward. While no single solution can fully address the challenges that Americans with chronic disease face, any solution should strengthen the connection between patients and their prescribed therapies, ensuring affordability and consistent access.

  • Getting to the Heart of the Matter: Maternal Health Challenges for Black Women Imperative to Fight Against Chronic Disease

    Becoming a new mother is often described as one of life’s most extraordinary experiences. Yet for many women, the period following childbirth is also marked by profound physical, emotional, and systemic challenges. As chronic diseases become increasingly common contributors to maternal complications and mortality, understanding and addressing the broader social determinants of health is essential to addressing the realities, especially those facing Black mothers and their babies. Black women and mothers face a disproportionately high risk for a range of cardiovascular conditions. According to the American Heart Association , Black women experience higher rates of hypertension, heart failure, peripartum cardiomyopathy, and stroke, often beginning earlier in life and progressing more aggressively than in other groups. Added elements like chronic stress, limited access to preventive care, and inadequate postpartum follow-up intensify these risks during pregnancy and motherhood. The Partnership to Fight Chronic Disease continues to shine a light on the disproportionate impact of chronic disease on maternal health outcomes. On December 3 rd , PFCD joins California State Senator Dr. Akilah Weber Pierson for another follow up event focused on supporting the health and wellness of Black mothers. This gathering will bring together clinicians, community leaders, researchers, and advocates to discuss how chronic disease management and equitable care access can transform maternal and infant outcomes. A Crisis Rooted in Inequity Black women in California are more than four times more likely  to die from pregnancy-related causes than white women. Nationwide, they are nearly three times more likely  to experience maternal mortality. These disparities cannot be separated from the chronic diseases that disproportionately affect Black women—conditions that often go undiagnosed, undertreated, or unsupported before, during, and after pregnancy. Black women are: 60% more likely  to have high blood pressure At significantly higher risk for diabetes and heart disease More likely to develop gestational diabetes , increasing future risk of Type 2 diabetes More likely to experience worsening hypertension postpartum , raising long-term heart disease risks These chronic conditions can complicate pregnancy, delivery, and recovery, yet the barriers Black women face in accessing consistent, culturally competent care often make managing these problems deeply challenging. Health outcomes are shaped by far mor e than biology. For Black mothers, the following factors play an outsized role in health outcomes : Limited access to high-quality healthcare Insurance gaps Financial stress Under-resourced neighborhoods Lack of culturally competent providers Distance from health facilities Collectively, these systemic inequities not only make it harder to receive timely and appropriate care but more broadly create an environment where Black women must not only adapt to life with a newborn but simultaneously navigate chronic conditions without the level of support they need and deserve. Chronic Disease: A Driving Force Behind Maternal Mortality The connection between chronic disease and maternal health outcomes is stark. From 2020 to 2021 alone, the U.S. maternal mortality rate rose by more than one-third. The rate for Black mothers was more than twice that for white mothers. Even before the pandemic, chronic diseases accounted for half of all maternal deaths  in the United States. They remain the fastest-rising cause of maternal mortality today. In San Diego County, Black infants are nearly three times more likely  to die during their first year of life and are 60% more likely  to be born premature—further demonstrating how chronic disease, inequity, and maternal health intertwine. Sickle cell disease, which disproportionately affects Black women, carries its own heightened risks and women with sickle cell are more likely to deliver younger, live in under-resourced communities, and experience stillbirth. PFCD remains committed to raising awareness, advocating for systemic change, and pushing for policies that eliminate racial discrimination in healthcare and address the social determinants that produce harmful disparities. To meaningfully reduce disparities and improve outcomes, we must: 1. Invest in culturally competent and accessible care. 2. Strengthen chronic disease prevention and management. From early screening to long-term management, prioritizing heart health, diabetes prevention, blood pressure control, and sickle cell care is essential. 3. Expand access to mental health services. Support must be affordable, stigma-free, and rooted in community understanding. 4. Address social determinants of health. Transportation, childcare, housing stability, nutrition, and economic security directly shape maternal well-being. 5. Drive policy based on equity and evidence. ALL mothers deserve not only survival but the opportunity to thrive. By prioritizing maternal health, addressing chronic disease, and confronting the systemic barriers that shape outcomes, we can build a future where every mother has the care, support, and dignity she deserves.

  • PFCD Responds on IPAY 2027 and Impacts for People Living with Chronic Disease

    November 26, 2025 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) announcement of the “maximum fair prices” for the 15 drugs selected for Medicare price-setting in 2027 under the Inflation Reduction Act (IRA): “Nearly 88% of U.S. adults aged 65+ rely on prescription medicines monthly, with 40% using five or more. When considering how best to improve overall health outcomes in the U.S., Medicare beneficiaries need robust access to innovative treatments. However, the IRA’s price-setting program and broader changes to Medicare Part D risk that access going forward. A recent analysis shows  that in response to the IRA, Part D plans are increasing out-of-pocket expenses and formulary barriers for beneficiaries, jeopardizing access for those who need treatment most.​ “The Part D drugs selected for Initial Price Applicability Year (IPAY) 2027 reflect significant cost and coverage implications for Medicare beneficiaries. Many of these medicines are already highly rebated, with seven of the 15 chosen medications having average estimated rebates exceeding 40% . These drugs were utilized by approximately 5.3 million Part D patients between November 2023 and October 2024, accounting for an average of less than $650 a month in Medicare spending per beneficiary – before rebates – during that period. Yet changes under the IRA have led plans to charge patients coinsurance instead of fixed copays, compounding out-of-pocket burdens for patients. “It is clear that the IRA’s price-setting approach to make drugs ‘more affordable for seniors’ will not deliver meaningful savings to patients, with insurers and pharmacy benefit managers (PBMs) merely shifting costs while continuing to profit. Instead of looking for ways to double-down on this approach, PFCD calls on policymakers to focus their attention on bipartisan solutions that protect patient access while also addressing affordability for patients themselves. This includes requiring PBMs to pass on negotiated savings to patients at the point of sale, delinking PBM compensation from the list price of medicines, prohibiting exploitative tactics like copay accumulators, and never allowing discriminatory measures such as the quality-adjust life year (QALY) to shape pricing and coverage decisions in the U.S.   “Making lower health care costs a reality for people managing one or more chronic conditions is not just a matter of price but also access to prescribed medicines that support better health outcomes. PFCD will continue to call attention to how the IRA’s price-setting is failing American seniors. Commonsense reforms that protect patient access must be a priority.”

  • Alzheimer’s Screening and Prevention (ASAP) Act Would Advance Early Detection and Streamline Access to Alzheimer's Care

    November 25, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to the introduction of the Alzheimer’s Screening and Prevention (ASAP) Act, legislation co-sponsored by Senators Susan Collins (R-ME), Catherine Cortez Masto (D-NV), Shelly Moore Capito (R-WV), Mark Warner (D-VA), and Representatives Vern Buchanan (R-FL) and Paul Tonko (D-NY) to empower Medicare to cover FDA-approved blood-based biomarker tests for the early detection of Alzheimer’s disease and other dementias.   "We applaud Sens. Collins, Cortez Masto, Capito, and Warner and Reps. Buchanan and Tonko for their leadership in advancing this bipartisan, bicameral bill to help make the latest Alzheimer’s early detection tools more widely accessible to patients. The societal burden of this disease is staggering; more than 7 million Americans are currently living with Alzheimer’s and  in 2025 alone, the total cost of dementia in the U.S. will hit $781 billion . Dementia requires direct medical and long-term care costs for families, as well as approximately 6.8 billion hours  of unpaid caregiving by family members and friends to people living with these diseases.   This bill represents a crucial step toward ensuring these tools reach the patients who need them most. Detecting Alzheimer’s disease at earlier, more treatable stages gives patients and families critical hope. The urgency cannot be overstated. Each day, an estimated 3,000 people with Alzheimer's progress beyond the reach of early-stage treatment.    “Recent medical advances have shown remarkable promise in detecting signs of Alzheimer’s even before symptoms appear. The FDA's approval of breakthrough blood-based biomarker testing earlier this year provides healthcare professionals with a less invasive and more accessible tool to detect Alzheimer's at early stages.   “However, these diagnostic innovations mean nothing if patients cannot also access the latest treatments for Alzheimer’s disease. Medicare's current approach of restricting access to FDA-approved Alzheimer's therapies through cumbersome coverage with evidence development (CED) registries creates dangerous delays. Such measures that condition coverage on research participation create administrative quagmires that prevent timely treatment, a dangerous precedent for patient access across chronic diseases.   “PFCD urges Congress to swiftly advance the ASAP Act and calls on policymakers to continue working to streamline access to treatments already deemed safe and effective.” ###

  • America is Not an Outlier in Key Drug Spending Metric

    The U.S. spends more on healthcare than any other nation, but that doesn’t mean it overspends on medicine.   According to the new IQVIA  Drug Expenditure Dynamics 2000 - 2022  report, 15% of America’s overall healthcare spending is allocated to drug expenditures. That percentage was also the average among the 12 developed countries IQVIA studied.   This means the U.S., when accounting for its overall healthcare spending, is not an outlier in how much it spends on drugs. By comparison, IQVIA found that Japan (20%), South Korea (19%) Spain (17%), Italy (17%) and Australia (16%) commit a greater share of healthcare spending to drugs.   This context is essential for shaping efforts to lower healthcare costs by reducing the prevalence and burden of chronic disease in America. For example, reducing people's access to treatment may lower costs in the short-term, but increases the burden of disease and long-term costs. Chronic conditions, which include heart disease, cancer, and diabetes, are the leading cause of death in the U.S. and account for 90% of overall healthcare spending. Improving population health is therefore one of the most effective long-term strategies for lowering healthcare costs.   It is true that the U.S, despite affordable generics, spends more on drugs than any other country in terms of absolute spending. But we also spend more overall and on specific healthcare services.   U.S. Drug Spending: Growth with Value While total pharmaceutical expenditures continue to rise in absolute dollars, much of that growth reflects medical  advances, not price inflation.   The U.S. prescription drug market reached roughly $487 billion in net spending in 2024, a 11.4% increase from 2023  amid new therapies for obesity, diabetes and oncology. Yet medicine price growth has remained flat or declined slightly, meaning utilization and innovation, not higher prices, are driving spending.​    When viewed in this context, medicines are a comparatively stable component of the system. Over the past decade, total U.S. drug spending has averaged only 2% annual growth when accounting for rebates and generics entering the market.   Despite that landscape, efforts to enact foreign-reference drug pricing in the U.S. are on the rise. The approach seeks to mandate that manufacturers provide American patients the same prices available in peer nations. While well-intentioned, the approach misdiagnoses the root cause of healthcare cost growth.​   Medicine prices are just one piece of the puzzle, and they’re not the fastest-growing piece. Hospital care, administrative overhead, and the burdening prevalence of chronic disease spending drive far more cost. Policies that focus narrowly on capping drug list prices risk limiting patient access to existing treatments and losing out on innovation for new treatments, especially for therapies that prevent complications and reduce hospitalizations over time.​   Other nations with lower drug prices accept trade-offs, including slower access to new therapies and fewer treatment options. Importing their pricing systems into the U.S. won’t guarantee lower costs for consumers. Significant rebates and discounts taken by pharmacy benefit managers, for example, never reach patients at the pharmacy counter.   A Smarter Way Forward If the goal is meaningful cost reduction, the solution isn’t blunt price-setting.   It’s smarter spending and lowering the need for avoidable healthcare services by preventing and reducing the burden of chronic diseases.   That means building value-based frameworks where payment reflects results, not volume. Medicines often prevent costlier hospital interventions, reduce ER visits, and save lives. Policies should seek to expand access to medicines to achieve system savings, not undermine them.

  • PFCD Statement on the GENEROUS Model: Importing Foreign Pricing Models is Not the Answer

    Nov. 12, 2025 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare & Medicaid Services’ (CMS) announcement of a new demonstration through the CMS Innovation Center, the GENErating cost Reductions fOr US Medicaid (GENEROUS) Model: “Given PFCD’s well-documented opposition to importing foreign price controls, we have strong concerns about CMS’s proposed GENEROUS Model, which would tie Medicaid prescription drug pricing to foreign ‘Most Favored Nation’ (MFN) benchmarks. Adopting prices from foreign countries means adopting the discriminatory cost-effectiveness standards those countries use to set prices and determine patient access, including the Quality-Adjusted Life Year (QALY). Each of the eight countries this model will use to calculate the MFN price —  the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland —  use QALYs  to inform coverage and pricing decisions. The QALY-based frameworks used in these nations have frequently led to treatment delays and care rationing for vulnerable populations, including older adults, individuals with disabilities, families navigating rare diseases and those with multiple chronic diseases. The adoption of such a strategy prioritizes government savings at the expense of patient-centered care and may, in fact, worsen access for Medicaid beneficiaries who already pay little or no cost-sharing for their medicines. “As the Trump administration continues to pursue MFN drug pricing proposals, we remain concerned about the impact these policies will have on people living with one or more chronic conditions. MFN poses a significant risk to patient access to prescribed treatments in the short-term and future innovations down the road. The adoption of foreign price controls will only serve to undermine the progress achieved through American medical research and erode incentives for developing the next generation of therapies and cures here in the U.S. “PFCD has long supported the goal of improving affordability for people living with chronic disease, but we urge policymakers to reject foreign pricing models that will not meaningfully improve patient affordability or access.”

  • Big Changes Coming to Medicare Drug Plans in 2026

    Medicare Open Enrollment starts this week and changes coming in 2026 warrant close consideration. Many will face fewer choices and higher costs, particularly for people who rely on traditional Medicare and purchase stand-alone prescription drug plans. Slightly less than half of Medicare’s 63 million beneficiaries enroll in traditional or fee-for-service Medicare (Parts A and B) compared to Medicare Advantage plans (Part C). Among rural beneficiaries, traditional Medicare is particularly popular. Beneficiaries who prefer traditional Medicare purchase stand-alone Part D plans for their prescription drug coverage. Fewer Plans to Choose From The Centers for Medicare and Medicaid Services (CMS) just released new data, and here’s the headline: the Medicare Part D market is shrinking again in 2026. The number of standalone prescription drug plans (PDPs)   will drop by 22%  - from 464 in 2025 to 360 in 2026 The number of Medicare Advantage plans with drug coverage (MA-PDs, not including Special Needs Plans) will also fall by 9% , from 3,246 to 2,967 over the same period That means fewer choices for people shopping for drug coverage this fall. Some insurance companies are pulling out of the market, while others are cutting back on the types of plans they offer. Interestingly, one area that’s still growing is Special Needs Plans (SNPs)   - these are designed for people with certain health conditions or lower incomes, and they’ll increase by 20%  next year. That’s good news for people living with specific needs, including serious chronic conditions, for which SNPs are available . Why All the Changes? The Inflation Reduction Act made significant changes to Medicare Part D. Some of these changes will help beneficiaries manage out-of-pocket costs, including the new annual out-of-pocket cap ($2,100 in 2026) and the Medicare Prescription Payment Plan. Launched in January 2025, the Medicare Prescription Payment Plan  offers seniors with any Medicare Part D plan (including PDPs or MA-PDs) the option to break their out-of-pocket prescription drug expenses into monthly installments to avoid having to make large payments earlier in the year. However, other aspects of the IRA, like the drug pricing provisions, risk undermining the Part D program. In 2026, the Medicare Prescription Drug Price Negotiation program kicks in for the first ten prescription medicines selected for price-setting. How the program affects beneficiary costs at the pharmacy counter and the impact on access restrictions will be closely watched. Expect Higher Premiums Even though Medicare is trying to limit premium increases, many people will still see their monthly drug plan costs go up in 2026. For those not receiving low-income help , average premiums for standalone drug plans are expected to rise by about a third. According to a new analysis by Avalere : About 1 in 4 people  will see their drug plan premium go up by $30 or more per month Around 17%  will see little to no change Most people with Medicare Advantage drug plans (MA-PDs)  will still have a $0 drug premium , but about 16%  will see an increase of $10 or more Fewer Choices for Low-Income Beneficiaries If you get help paying for your drug plan through the Low-Income Subsidy (LIS) , your options are also narrowing. The number of benchmark plans  - the ones available at no extra cost - will dip slightly from 90 in 2025 to 88 in 2026. This erosion of choices continues an alarming decline in the options of LIS plans for low-income beneficiaries. In 2023, before passage of the IRA , there were 191 LIS plan options. In some states, that means people will have only one or two of these no-cost plans to choose or face picking a plan for which they must pay premiums. What This Means for You Bottom line? The 2026 Medicare open enrollment will involve fewer plans and higher premiums . If you’re on Medicare, it’s going to be more important than ever to review your plan during open enrollment this fall. Even if you’re happy with your current plan, take a few minutes to compare your options - you might find that your plan’s price or drug coverage is changing.

  • What They Are Saying about "Most Favored Nation"

    The Partnership to Fight Chronic Disease opposes the Trump administration’s “Most Favored Nation” drug pricing proposal because it would import international price controls that threaten patient access, adopt discriminatory metrics of value, pose ethical concerns and stifle U.S. medical innovation.  Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the “Most Favored Nation” pricing proposal on patient access in America:  *DOWNLOAD INFOGRAPHIC * Alliance for Aging Research :  “Just as worrisome, international reference pricing policies effectively endorse the use of discriminatory cost-effectiveness standards often used by other governments. Many countries likely to be referenced, such as the United Kingdom and Canada, make drug reimbursement and coverage decisions based on cost-effectiveness assessments that are measured by the quality-adjusted life-year (QALY). These assessments assign a financial value to the patients for whom a given treatment is intended. The Affordable Care Act banned the use of QALYs for coverage and reimbursement decision-making in the Medicare program.  “QALYs originated in the 1960s and have been used by the British government to ration health care for its National Health Service. If we embrace an MFN-type reference pricing policy, it means embracing health care rationing as well. This type of rationing in many European countries has not only resulted in access issues but has also translated into higher mortality rates for chronic diseases, such as cancer. ”  American Society of Clinical Oncology : “High drug prices in the United States must be addressed, but MFN would impose a nationwide, mandatory experiment on people with cancer and their providers that could significantly restrict patients’ access to care—without any evidence that it will actually cut care costs .” Asthma and Allergy Foundation of America :  “The U.S. health care system is complex, and pushing on one lever to reduce costs may unintentionally increase costs to patients by other mechanisms. Without addressing all of the root causes, policies like MFN risk reducing availability or shifting costs elsewhere in the system, which could delay access or limit options for patients. ” “...we are deeply concerned that the proposed Most-Favored-Nation (MFN) pricing framework—while well-intentioned—fails to address the underlying complexities of the U.S. drug pricing ecosystem and risks creating unintended consequences that could restrict access for patients who rely on life-saving medications.” Caregiver Action Network :  “People on Medicaid already have broad access to medicines at little to no cost-sharing. The MFN model could lead to cuts in Medicaid and reduced access to lifesaving treatments for vulnerable populations. ” Coalition of State Rheumatology Organizations : “CMS also acknowledged that ‘beneficiaries may experience access to care impacts,’ including difficulty finding  providers and extended traveling to seek care. These are alarming forecasts  about the future impact of these proposals if applied to Medicaid, which we believe should sufficiently deter members of Congress from advancing this proposal.” Council for Affordable Health Coverage : “Entering critical steps to enact budget reconciliation, Congress should focus on dismantling the drug price control regime that already exists in the U.S. health care system, such as those enacted by the Biden administration in the Inflation Reduction Act — not reinforce it with a European model. European price controls are controversial because they restrict access to treatment, promoting worse health outcomes that cost more. Replacing efforts to control fraud in Medicaid with controversial price controls will hold up progress on the budget bill and should be rejected by Congress.” Healthy Men : “Time and time again, across numerous market sectors, artificially setting prices using foreign reference pricing has been unsuccessful. And when applied to pharmaceuticals,  it could ultimately harm patients and undermine the administration’s important goal of ‘Making America Healthy Again’. ” Let My Doctors Decide : “MFN may appear to lower costs on the surface, but in reality, it imports price controls that could restrict access to life-saving therapies. Countries whose pricing models would be adopted under this proposal routinely deny or delay access to innovative treatments —this includes patients battling cancer and other chronic, complex conditions that need access to new and existing ground-breaking treatments.” National Minority Quality Forum : “The MFN model would encourage a standardization of treatment options, moving away from personalized medicine toward a more limited formulary of options that satisfy price constraints. This is especially concerning for a nation as diverse as the United States , which serves populations with widely varying health needs and often complex, co-occurring conditions” “While making medications more affordable is an admirable goal, applying this price control strategy may unintentionally harm the very patients it aims to help—not just the 77 million Americans on Medicaid, but potentially all Americans if expanded throughout our healthcare system.” Part B Access for Seniors and Physicians (ASP) Coalition : “Linking U.S. health care policy to other countries, that artificially suppress prices through access restrictions and subjective controls, would tie the hands of providers in the United States by narrowing and delaying access to available treatments due to market forces outside of their control. Moving forward with this MFN… would irrevocably change health care in the country by disrupting provider’s ability to deliver patient-centric care  and upending the future development of innovative medicines.” RetireSafe : “By giving other nations the power to effectively control Medicare prices, MFN will decrease access to treatments seniors rely upon. Furthermore, altering the Medicare market could have unintended or unforeseen side effects on senior treatments more broadly, as well as premium costs, and mirroring smaller socialized healthcare markets  would only upend a working program and cause larger cost issues in the long term. ”  Former Congressman Michael Burgess, MD in Dallas News : “Those countries’ socialized health care systems achieve their lower prices, in large part, by negotiating prices which results in routinely delaying or denying access to new therapies. Older adults, people with disabilities, and patients with complex or rare conditions often lack access to lifesaving medicines in those systems. Adopting other countries’ prices would mean far fewer medical advances, and ultimately lead to the same access restrictions that patients face abroad. ” Former Congressman Larry Bucshon, MD in Indy Star : “ If it takes effect, companies will simply stop investing in most new drug research. It's simple economics — kill the potential return, and you kill the risk-taking too.  That'd come at a massive human cost.  New drugs have been responsible for more than a third of the decline in cardiovascular deaths since 1990. They've turned certain cancers from imminent death sentences into manageable, even curable, conditions. Now we're seeing promising treatments for obesity, ALS, and rare genetic disorders. Imagine telling families that future breakthroughs won't be coming — because we chose to import foreign price controls .”

  • PFCD Fact Sheet: Building a Stronger Future Through Prevention and Innovation

    Childhood health lays the foundation for lifelong health, influencing whether adults thrive or struggle with preventable disease. A solid foundation in childhood creates healthier populations, stronger communities, and a more resilient nation while decreasing the burden on the U.S. health care system. Using new research that will be featured in a broader analysis of medical and economic costs associated with chronic disease among adults, the Partnership to Fight Chronic Disease created a one-page fact sheet  to capture the current state of health for US children and what lifestyle and treatment improvements could mean. Data shows that the U.S. is projected to spend $1.15 trillion over the next 15 years on chronic diseases occurring during childhood, such as asthma, cancers, and obesity. This burden not only disadvantages children and their families, but adds costs for hospitals, schools, and workplaces alike. Prevention, better management, treatment advances, improved adherence and enhanced coverage all represent opportunities that could cut these costs by more than half while saving lives . Children today face personal health challenges unique from ones their parents faced. For example, technology such as video games and social media provide mental stimulation for children that discourage physical activity. Given the prevalence of screen time, it’s no surprise that less than half of high school students meet activity guidelines. Policies that encourage physical activity are increasingly important in the fight for better health, particularly for children. Social media also heightens risks of mental illness. One in five adolescents has a diagnosed mental or behavioral condition, most often anxiety. Among those needing mental health support, more than half report difficulty accessing essential treatment or counseling services. Research and development to drive improvements in medical technology and other tools to prevent and manage chronic disease in children remain essential. Advances in childhood cancer treatments already show what is possible with the potential to save more than 10,000 additional lives. Innovation in prevention and chronic disease management could avert millions of future cases. Policymakers have the opportunity and the responsibility to act. Prioritizing children’s health through sustained investment in research, development and innovation will save lives, reduce costs, and strengthen America’s future. Childhood health is not merely about today. It’s about every stage that follows.

  • Prevention Should Be Primary, But Making America Healthy Requires Much More Than That

    Sept. 11, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) has released the following statement in response to the Make Our Children Healthy Again Strategy report. “More than 40% of U.S. children and adolescents have at least one chronic condition, a concerning trend that deserves data-driven research and recommendations. The Make America Healthy Again Commission correctly highlights that improving nutrition, increased physical activity, reduced stress, and curtailing exposure to toxins are essential to health promotion for children. Given the desire to reduce exposure to toxins, we were troubled to see no mention of tobacco use and nicotine addiction prevention and cessation anywhere in the report. Tobacco use remains a major preventable cause of chronic disease, and nearly 90 percent of adults who smoke started before they turned 18 . “Even more concerning is the Commission’s emphasis on ‘overmedicalization’ as a ‘driver behind the rise in chronic disease,’ imprecisely calling it a ‘concerning trend … often driven by conflicts of interest in medical research, regulation and practice.’ Medicine is not the enemy of prevention; it is its partner: ·         One in 15 U.S. children has asthma , and inhalers and other therapies keep symptoms under control and prevent hospitalizations. Preventing exposures to triggers is important to avoid asthma attacks but is not enough for many without the support of medicines that prevent attacks and rescue medicines needed during one. ·         For the 300,000 children and adolescents living with type 1 diabetes , insulin is not optional but life-sustaining. ·         Advances in pediatric oncology have raised the five-year survival rate for childhood cancers above 85% , a direct result of research and treatment. "Getting regular exercise and spending time outdoors certainly do have beneficial effects on stress levels and mental wellbeing. However, to suggest that those activities alone can prevent and treat diagnosed mental illnesses diminishes the reality of these diseases, reinforces stigmas that prevent people from seeking treatment, and risks the health of children and adolescents suffering from mental illnesses. Medical care does not create chronic disease, but rather it allows children to live longer, healthier lives. Suggesting otherwise risks stigmatizing families who depend on these treatments and undercutting the value of efforts focused on delivering innovative treatments and cures to those living with unmet needs. “Any effort to make America healthy should prioritize prevention while also leveraging current and future treatments to better manage the existing toll of chronic disease across the U.S. The best path forward is to invest in healthier environments while strengthening research and health care that saves children’s lives. A comprehensive approach to children’s health must value both prevention and medicine.”

  • Gutting Medi-Cal’s weight loss drug coverage will cost California more in the long run

    By Kenneth Thorpe https://calmatters.org/commentary/2025/08/weight-loss-drugs-medi-cal/ California just cut off access to critical anti-obesity drugs for hundreds of thousands of patients. Under the new budget signed by Gov. Gavin Newsom, Medi-Cal — the state’s Medicaid program — would no longer cover weight loss drugs, such as Wegovy and Zepbound, unless they’re prescribed to treat diabetes. The measure is intended to promote fiscal responsibility . By cutting this drug coverage, policymakers say they’ll be able to save more than $600 million by 2029.  But they’ve got it all wrong. Obesity is a significant driver of skyrocketing health care spending because it’s a major risk factor for other costly, chronic conditions. Keeping evidence-based obesity treatments like these drugs accessible would more than pay for itself in the long run by making Californians healthier and more productive.  In California, roughly 3 in 5 adults are overweight or obese, including disproportionate numbers of low-income Californians and people of color. That puts them at higher risk of developing numerous other chronic conditions, including Type 2 diabetes, heart disease and certain cancers. Overcoming those risks can be challenging, especially given that genetics alone may account for up to 70% of people’s differences in body weight. That’s a major reason why lifestyle interventions alone have been largely unsuccessful at stopping the spread of chronic conditions — and why the arrival of anti-obesity drugs in recent years has been so revolutionary. In 2023, Medi-Cal’s coverage of the drugs for weight loss allowed more than 660,000 Californians to obtain the life-changing treatments. That same year, the national obesity rate dipped for the first time in a decade. The rapid uptake of these drugs hasn’t merely improved people’s lives. It also has provided policymakers with a new way to downsize health care spending. Some of my recent research, published in JAMA Network Open, highlights the significant link between weight loss and lower health care costs . Among Medicare beneficiaries with obesity and at least one other related health condition, like diabetes, just a 5% decrease in body weight was associated with a $1,262 drop in annual health care spending, or 7% in savings on average. A 25% weight reduction — which is not at all uncommon among people on anti-obesity drugs — led to an astonishing $5,442 drop in yearly health care costs, or 31% in savings. This suggests Newsom’s plan to slash health care spending by withdrawing coverage for these drugs could actually increase health care spending in the long run. According to Newsom, covering the drugs under Medi-Cal would cost California $85 million in fiscal year 2025-26, rising to $680 million by 2028-29. Those figures are overestimates, even before accounting for the savings from improved health. Once federal matching funds and drug manufacturer rebates are factored in, the true upfront cost to California would be much lower. The state’s supposed savings also pale in comparison to the cost of untreated obesity, which in 2022 depressed economic activity in California by nearly $90 billion and cost state government more than $10 billion in direct health care spending and foregone tax revenue, according to an independent report. Based on the research I’ve done, California could save about $3,000 per patient by continuing to cover weight loss drugs. It’s true that anti-obesity drugs require substantial upfront outlays from Medi-Cal. But it’s far more cost effective than paying for patients’ health complications down the road. Continuing that coverage is a smart investment in California’s future.

  • “Most Favored Nation” Drug Pricing Policy Threatens Access, Increases Discrimination, and Undercuts Efforts to Make America Healthy

    August 1, 2025 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to President Trump’s most recent efforts to impose “Most Favored Nation” (MFN) drug pricing, which poses considerable risks to patient access, particularly to people living with one or more chronic diseases. “More than one in two adults in the U.S. lives with at least one chronic condition and nearly one in three live with two or more chronic conditions. As such, chronic diseases are the primary driver of health care costs—accounting for 90 cents of every dollar we spend on health care in this country. The burden of chronic disease is clearly one of the costliest challenges we face as a nation and must be a top priority for policy reform. “With that top of mind, PFCD   strongly opposes the Administration’s latest efforts to call for MFN pricing and warns that tying U.S. drug prices to foreign price controls would limit patient access to life-saving treatments, stifle medical innovation, and disproportionately harm those with chronic conditions. “While intended to reduce drug prices, an MFN policy would import foreign price controls from countries that use discriminatory pricing measures like the quality-adjusted life year (QALY) to ration health care. These types of cost-effectiveness measures systematically devalue the lives of seniors, people with disabilities, and those with chronic diseases to deny them access to the treatment their doctors recommend. “Added concerns about how MFN policies would negatively impact people living with chronic disease include: Delays and Denials of Care: Countries the MFN policy seeks to emulate routinely ration care, leaving patients waiting years for access to innovative treatments, if they ever get access at all. Ethical Risks of Foreign Price Controls: MFN would allow foreign governments to dictate what treatments are available to American patients, undermining patient and provider choice. Provider Reimbursement Cuts: MFN’s slashing of reimbursement rates would force providers, particularly in rural and underserved communities, to reduce or eliminate participation in public health plans, further shrinking access for vulnerable populations. Stifling U.S. Medical Innovation: Pegging U.S. prices to foreign benchmarks erodes incentives to develop the next generation of cures for cancer, Alzheimer’s, and other chronic diseases. Threats to Personalized Medicine and Equitable Care for All Who Need It: MFN prioritizes cost over care, hitting minority populations and patients with complex chronic conditions hardest by limiting treatment options. “PFCD urges policymakers to reject MFN and pursue more patient-focused solutions to address rising out-of-pocket costs, like reining in PBMs and insurers. To truly make America healthy, policymakers should seek to expand access to affordable medicines without compromising care quality, innovation, or patient choice.” ###

  • Partnership to Fight Chronic Disease Applauds Senate HELP Hearing on Costly Systemic Abuse

    July 31, 2025 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) has issued the following statement in response to the Senate HELP Committee hearing, “Making Health Care Affordable: Solutions to Lower Costs and Empower Patients”: “The Senate HELP Committee did the American public a tremendous service when guiding today’s informative and eye-opening discussion. We appreciate the leadership of Chair Cassidy, Ranking Member Sanders, and all members of the Committee for addressing the pressing challenges of cost and access in our health care system. “The hearing underscored the growing burden of chronic disease and the structural barriers that make it difficult for patients to manage their health effectively. Conditions such as cancer, diabetes, heart disease and depression affect tens of millions of Americans. For many, coverage decisions, shifting formularies, and limitations on pharmacy access create delays in care, financial stress, and worsened health outcomes. “The Committee’s focus on the role of intermediaries, including pharmacy benefit managers and insurers, is especially important. The impact of opaque pricing and coverage practices reaches across every community, and the need for greater accountability is clear. “We welcome continued collaboration on policies that prioritize the needs of people living with chronic conditions. A stronger commitment to transparency, affordability, and continuity of care will help ensure that individuals can manage their health without encountering unnecessary obstacles. “We thank the Committee once again for convening this important hearing.”

  • Critical Moment Looms for MAHA Commission, U.S. Mental Health

    There is never a wrong time to talk about mental health. For millions of Americans, the challenge exists daily, shaping how they connect and cope with their surrounding environment. Here in July, the conversation is especially timely: It is National Minority Mental Health Awareness Month. Mental health, like other chronic conditions, places a disproportionate burden on historically marginalized communities. Higher rates of trauma, discrimination, and chronic stress compound the prevalence and severity of mental illness. Meanwhile, systemic barriers can delay diagnosis and restrict access to care. The Make America Healthy Again Commission recently recognized mental health as essential for national health. This is an important distinction to explore. For nearly two decades, the Partnership to Fight Chronic Disease has observed how mental health influences outcomes across care. People managing diabetes, heart disease or asthma may struggle more to pursue or adhere to treatment when depression or anxiety is left untreated. Of course, acknowledgment is not enough. The MAHA Commission must follow up with recommendations that appropriately recognize high-risk groups. Young people at large, for example, are subject to immense pressure. School demands, social isolation, and online stress contribute to the crisis. Suicide is one of the three leading causes of death for children, adolescents and adults between ages 10 and 24. In rural areas, the situation is especially urgent. Rural residents experience higher rates of depression and rates of suicide relative to Americans in urban communities. Limited access to care further exacerbates the issue. Not only do rural areas have 20% fewer primary care providers than urban areas, but 65% of rural counties lack a single psychiatrist and 95% don’t have a pediatric psychiatrist. Telehealth could help fill the void, but one in three rural homes lacks the requisite internet connection. Risks are also high for LGBTQ+ youth and youth of color. From 2007 to 2020, the suicide rate among Black youth ages 10 to 17 rose by 144%. Teens who identify as gay, lesbian, or bisexual are more than three times as likely to consider suicide than their heterosexual peers. These numbers reflect a system that has failed too many for too long. PFCD understands the opportunity at hand to share practical recommendations as well as the importance of getting the messaging’s language right. Some phrasing in the MAHA Report risks reinforcing outdated, harmful myths, such as that therapy “encourages rumination,” the suggestion that parents or schools are to blame, or that medication and counseling are signs of weakness rather than valid treatments. When mental illness is framed with blame or stigma, people stay quiet. Likewise, language within the MAHA Report supported the notion that depression and other mental illness is over-treated among adolescents. Research says otherwise. According to the National Institute of Mental Health, only 40.6% of U.S. adolescents with a major depressive episode received treatment — and only 44.2% who suffered a major depressive episode with severe impairment. Given the mental health crisis in youth, our greater concern is under-diagnosis and under-treatment of mental illness, particularly among underserved and marginalized communities. It can be counterproductive to broadly stigmatize treatment for children in need of behavioral and medical intervention, including access to effective medications when appropriate. Mental health should be embedded in every effort to modernize care. That means better infrastructure, expanded telehealth, more trained providers, and full parity for insurance coverage. The Commission is on the right track to recognize mental health as a chronic mental condition deserving of parity in care and coverage. PFCD stands ready to help advance the momentum. There is never a wrong time to talk about mental health. There is no better time than now to act.

  • Fighting Alzheimer’s Shouldn’t be a Bureaucratic Battle

    By Candace DeMatteis, PFCD Policy Director Alzheimer’s disease is a devastating fatal disease, causing progressive damage that steadily erodes memory, thinking, and daily functioning. Alzheimer’s is the most common cause of dementia – an overall term for a group of neurological conditions affecting cognition, memory, communication, problem-solving, and concentration – that involves specific brain changes, including the excessive accumulation of the protein beta-amyloid and tau proteins. Today, approximately  7.2 million Americans  age 65 and older are living with Alzheimer’s. The societal burden of this disease is staggering; in 2025 alone, the total cost of dementia in the U.S. will hit  $781 billion . Dementia requires direct medical and long-term care costs for families, as well as approximately 6.8 billion hours of unpaid caregiving by family members and friends to people living with these diseases.  Fortunately, recent and ongoing research has shown promise. Medical progress has given us an opportunity to slow disease progression – and one day, could help do so even before symptoms appear. Yet despite the growing promise and treatments currently available to slow the disease, Americans battling Alzheimer’s continue to face enormous hurdles that block access to timely, effective care. These challenges begin with delayed diagnoses and extend through treatment, with disproportionate impacts on underserved communities. One of the most significant barriers today stems from Medicare’s decision to restrict access to FDA-approved Alzheimer’s therapies by requiring enrollment in  cumbersome coverage with evidence development (CED) registries . While meant to support research, conditioning Medicare coverage on participating in research creates administrative quagmires. For patients, their loved ones and caregivers these delays are more than just frustrating – they’re dangerous. Each day, an  estimated 3,000 people with Alzheimer’s  may progress beyond the reach of early-stage treatment. The process patients and their physicians must navigate --ranging from an often lengthy journey to diagnosis to insurance hurdles all along the way -- highlights the added and unnecessary barriers to care. This approach not only threatens current access but sets a precedent for future therapies, potentially deterring innovation and investment in the Alzheimer’s space. It’s time for policymakers to act. Washington can clear the path for Alzheimer’s disease. We must streamline access to treatments already deemed safe and effective .  It’s time to shift the focus from red tape to real solutions – for the millions of Americans who can’t afford to wait.

  • 5 Things to Know: The MAHA Report

    More than 40% of U.S. children and adolescents have at least one chronic health condition , such as asthma, allergies, obesity, and behavioral or learning challenges. In a recent 73-page report , the Make America Healthy Again (MAHA) Commission confronted the growing crisis, spotlighting underlying challenges like poor diet, environmental exposures, increased screen time, and a lack of physical activity. The Partnership to Fight Chronic Disease (PFCD) welcomes this focus and emphasis on prevention. But to truly maximize the moment and achieve long-term improvements, recommended solutions must be rooted in science and facts, representativeness, and real-world feasibility. Below are five key takeaways from the MAHA Report — along with PFCD’s perspective on where it hit the mark and where elaboration or clarification is needed. 1.      Ultra-Processed Foods (UPFs) Pose Significant Challenges   The report calls out poor diet — particularly the prevalence of UPFs in American diets — as a leading driver in pediatric chronic illness. It notes that nearly 70% of children's calories come from UPFs, which are heavily processed products linked to obesity, diabetes, and metabolic dysfunction.  PFCD agrees that improving the American diet across all ages presents a significant opportunity to improve health. But the report oversimplifies the problem, ignoring key drivers like food affordability and access exacerbated by aggressive advertising. To shift eating habits at scale, policymakers must confront food deserts, invest in nutrition education, and make healthy options accessible and affordable for all families. Recommendations as to the types of food are also important, as science supports plant-based diets and the consumption of whole foods. 2.      Environmental Chemical Exposure Is a Growing Concern   Concern over environmental toxins such as PFAS, phthalates, microplastics, and certain food additives was strongly iterated in the report. The MAHA Commission called for stricter research and regulatory action to reduce exposure. PFCD agrees that   environmental health plays a key role in chronic disease prevention. A narrow focus on individual chemicals, however, risks missing systemic issues that affect vulnerable communities most. Broader action is needed — from addressing pollution in marginalized neighborhoods to improving housing and infrastructure. Environmental factors must be part of the chronic disease conversation. 3.      Physical Inactivity and Chronic Stress Are Key Factors   The Commission identified increased screen time, sedentary behavior, and chronic stress as core contributors to the decline in children’s physical and mental health. We agree, these are serious concerns. But without tackling social determinants like unsafe neighborhoods, poverty, family stress, and a lack of recreational infrastructure, the report’s recommendations fall flat. Real solutions require in-depth analysis into the core causes of these behavioral changes. That way, strategic investment in schools, communities, and public spaces that support movement, connection, and resilience can be executed. 4.      Medical Treatment and Prescription Drug Use Are a Symptom, Not the Problem Prevention is paramount when it comes to health improvement, but preventive lifestyle interventions can and should coexist with medical interventions when needed to reduce health risks, treat disease, and prevent complications. The report warns of growing reliance on medications for children and adolescents, including antidepressants, antipsychotics, GLP-1s for obesity, and antibiotics, while questioning the safety and necessity of some treatments. Appropriate medication use is important in the fight against chronic illness, including risk reduction and complication prevention. The report’s treatment of topics like vaccines and mental health threatens to undermine proven and medically appropriate interventions that are vital to prevent and manage chronic disease. The report, for example, makes misleading assertions about the childhood vaccine schedule and FDA standards and approvals. Vaccines offer protection against a host of high risk, high impact infectious diseases and as such are foundational to the health of America’s children. Rather than casting unfounded aspersions against health care providers, medical journals, and both public and private scientific and medical experts, we must focus on opportunities to prevent mental illness and reduce stressors while expanding access to diagnosis and treatment for those suffering in order to make a difference. Stigma plays an outsized barrier to seeking care, particularly for adolescents. Criticizing parents and health care providers that seek and provide medical treatment will only exacerbate those issues instead of providing necessary supports to improve health outcomes. 5.      The Report Calls for a National Strategy - But Lacks Evidence and Nuance The Commission proposes a national strategy by August and outlines 10 areas for further research, covering everything from reduced-UPF diets to vaccine safety. Research must be unbiased, rigorous, transparent, replicable, and subject to peer review. The report omits several critical issues tied to childhood chronic disease, such as maternal health, gun violence, and substance use, while also citing non-nationally representative studies. Reputable scientific inquiry to identify policy solutions requires drawing conclusions from the evaluation of accurate peer-reviewed data. A meaningful national strategy must reflect the full spectrum of health determinants, grounded in the best available facts and analysis led by the data instead of a search for data points to support predetermined conclusions. The MAHA Report puts an urgent issue front and center: the health of America’s children is at risk. To truly address this crisis, urgency cannot come at the expense of broad input from medical, scientific, patient, and consumer communities. The lack of a public comment on the MAHA Assessment Report limited its accuracy and viability as a rallying cry for change. We strongly urge the Administration to allow for public review and comment on the MAHA Strategy Report that will follow. PFCD believes lasting progress demands a strategy that aligns science, policy, and lived experience. We’re committed to working with our partners, policymakers, and health and community advocates to ensure that any national strategy to address childhood chronic disease reflects both the complexity and opportunity of building a healthier future for all children.

  • Partnership to Fight Chronic Disease Urges Lawmakers to Address Ongoing Gaps that Undermine Patient Access and Innovation, Build on Reforms

    May 15, 2025 (WASHINGTON, D.C.) – The Partnership to Fight Chronic Disease (PFCD) today issued the following statement in response to the House Energy and Commerce Committee’s advancement of reconciliation legislation: “Medicaid is a lifeline to millions of Americans living with chronic diseases and disabilities. PFCD shares concerns about the health and financial impacts of Medicaid cuts on America’s most vulnerable populations. We urge policymakers to tread carefully to avoid diminishing access to the care needed to improve health in America and on which 72 million Americans rely. “At the same time, we support several reforms included in the measure, including provisions increasing transparency, fairness, and accountability among pharmacy benefit managers (PBMs) in Medicaid and Medicare Part D, which enjoy bipartisan support. Reforms like this are essential to improving access and affordability for the more than 190 million Americans living with one or more chronic conditions. “We also support changes to provisions in the Inflation Reduction Act (IRA) that disincentivize researching FDA approved medicines for rare diseases. Inclusion of the Orphan Cures Act addresses that deeply problematic provision in the IRA and will encourage much needed research. “The House, however, left unaddressed another bipartisan IRA reform effort, the Ensuring Pathways to Innovative Cures (EPIC) Act. The EPIC Act would ensure that small-molecule medicines, often preferred by patients because they are easier to take at home, receive the same 13-year exemption timeframe as biologics under the Medicare Drug Pricing Program. Without that reform, the research and development shift away from small-molecule drugs will continue to the detriment of the millions of Americans with unmet medical needs. We encourage the Senate to include this needed reform when they take up the package. “PFCD strongly urges lawmakers to make progress on reform efforts by pursuing comprehensive, patient-centered solutions that promote health, protect access and coverage, enhance medical innovation, and ultimately reduce the burden of chronic disease on individuals, families, and the U.S. health care system.” ###

  • May 19 Webinar - Medicare Prescription Payment Plan: What New Data Tells Us About Access and Cost

    FULL VIDEO RECORDING The Medicare Prescription Payment Plan: What New Data Tells Us About Access and Cost

  • April 30 - Symposium: Prevention & Treatment of Chronic Disease in the Southeast

    PFCD Chair Ken Thorpe & the Partnership to Fight Chronic Disease (PFCD) invites you to join us for this hybrid event focused on an array of issues related to prevention and treatment of costly chronic conditions. SYMPOSIUM PRE-READ DOCUMENT FULL VIDEO RECORDING Symposium: Prevention & Treatment of Chronic Disease in the Southeast Questions? Jennifer.Burke@fightchronicdisease.org

  • Partnership to Fight Chronic Disease Urges President Trump to Withdraw "Most Favored Nation" Executive Order Threatening Innovation and Patient Access to Treatment

    May 12, 2025 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD ) issued the following statement in strong opposition to President Donald Trump’s "Most Favored Nation" (MFN) executive order, which aims to tie prescription drug prices in the U.S. to those in foreign countries: “President Trump’s Most Favored Nation executive order mistakenly assumes that America can maintain its world-leading medical innovation while adopting the same foreign government price controls he has long criticized. The unintended consequences of this policy proposal would not only paralyze research, development, and innovation in America but would cause disruption across the U.S. health care ecosystem. Threatening access to lifesaving medicines and discouraging the discovery of breakthrough treatments, especially for millions living with one or more chronic conditions, seems quite counter to efforts aimed at making America healthy now or in the future. "If implemented, this executive order would effectively import the very systems of government intervention that stifle innovation and restrict access abroad. It would have the same harmful impact here at home, undermining progress in treating chronic conditions, like diabetes, cancer, heart disease and many rare diseases in the United States. "Pharmaceutical price controls disproportionately harm the most vulnerable, including both Medicaid and Medicare beneficiaries. These patients deserve better solutions focused on improving their care and overall health outcomes, not policies that delay or deny access to critical treatments. “Compounding these concerns, foreign price setting systems often rely on discriminatory value assessments that restrict access based on a person’s age, health status, or disability. The National Council on Disability has documented these harms, and PFCD stands firmly against discrimination in all forms. “Well more than half of American adults live with at least one chronic condition, and chronic disease accounts for the majority of U.S. health care spending. With the potential to save and improve lives through continued medical advancement, now is the time to foster innovation, not hinder it with misguided policies that are not focused on the realities for patients. “We urge President Trump to immediately withdraw this executive order and instead pursue solutions that protect both patient access and innovation. Americans’ health must be the priority.”

  • Medicaid Patients at Risk of Losing Ground Against Chronic Disease

    There is no ignoring the facts. The United States faces a chronic disease crisis, and the Trump administration is correct to prioritize addressing it. Conditions like diabetes, cancer, and heart disease affect more than half of U.S. adults and account for 90% of health care spending. Meaningful reforms must prioritize prevention, improve access to recommended care, and support innovation in treatment and care delivery. A healthier America means lower health costs, better quality of life, and a stronger, more productive economy. But another truth is undeniable: The drive to defeat chronic disease stalls if Medicaid patients are placed in the backseat. That’s what makes a recent policy push so counterproductive. The “most favored nation” (MFN) drug pricing proposal being floated in Washington threatens to sink access for millions of chronic disease patients. It would tie Medicaid drug reimbursements to the lowest prices set by foreign countries, where drug pricing is often based on criteria that discriminates against older people, people living with disabilities, and others whom Medicaid is designed to protect. Medicaid currently guarantees the lowest price in the market, as manufacturer rebates reduce drug costs by more than 50% on average. Importing drug prices from countries with discriminatory coverage practices would upheave the system, exposing an already vulnerable population to increased medical complications. Medicaid-enrolled adults (ages 19-64) report higher chronic condition rates than privately insured adults (75% vs. 66%), and nearly one-third report three or more chronic conditions. Medicaid provides essential health care to over 70 million Americans—including a reported 37 million children, millions of seniors, people with disabilities, veterans, caregivers, and low-income working families. It ensures children who need it can access home nursing care, helps veterans and caregivers manage chronic and mental health conditions, supports rural hospital operations, and enables seniors to live independently. Today, the federal program is far from perfect, but it is a lifeline for those who need it, many millions of Americans who are among the most vulnerable in our country. For individuals living with chronic illnesses, intellectual disabilities, cancer, diabetes, or behavioral health conditions, Medicaid is often the only pathway to care. Women, particularly those facing serious diagnoses like breast cancer, and workers in low-wage jobs without employer health coverage, also rely heavily on the program. Research shows Medicaid beneficiaries face provider shortages in every state. Low reimbursement rates make it difficult for patients to find doctors who accept Medicaid — and even harder to receive the consistent, high-quality care required to optimize medical outcomes.   Disrupting reimbursement rates would only increase access barriers for low-income Americans. The MFN approach also endangers the future of medical innovation. The U.S. leads the world in drug discovery because of a market-based system that rewards the development of new therapies. Tying reimbursement to foreign price controls risks choking investment in research and development, just as chronic diseases are poised to rise. Over the next five years, up to 15 million more Americans could be diagnosed with a chronic illness. An estimated 9 million could lose their lives to these diseases. Yet thousands of promising treatments are in development — therapies that could extend life, prevent hospitalizations, and reduce health care costs. This is a time to encourage such discovery, not disincentivize it. The Partnership to Fight Chronic Disease was founded in 2007. Across the nearly 20 years since, various administrations have been largely asleep at the wheel on chronic disease despite the rise in obesity and other related conditions that have worsened the strain on our health care system. The Trump administration’s grip on the wheel and eyes on the road are a welcome change of pace. Still, wrong turns happen. This latest proposal would put the health, dignity, and economic security of these communities at serious risk—forcing hospitals to reduce services or close, eliminating preventive care, and pushing already vulnerable patients into crisis. Medicaid isn’t just a program—it’s the foundation of health access for millions. Congress must dismiss this misguided, risky proposal that would severely jeopardize the vision to make America healthy again.

  • Statement from Former Rep. Larry Bucshon, MD, in Response to Trump Administration Executive Order

    April 18, 2025 (Washington, D.C.)  The Partnership to Fight Chronic Disease released the following statement on behalf of PFCD policy adviser and former Representative Larry Bucshon, MD, in response to the Trump Administration’s executive order: “With one signature, President Donald Trump potentially did more for U.S. health care than another person in the Oval Office might in a year. The executive order he signed this week showed great pulse and clear direction on several issues influencing the quality and accessibility of patient care, many of which directly impact my older friends on Medicare. “As a cardiothoracic surgeon, I appreciate medicine’s power to improve health outcomes. I also recognize the many environmental and lifestyle factors that exist outside a medical facility. How closely patients adhere to their drug prescriptions at home is among those external factors. Small-molecule drugs— the pills, tablets, and capsules that occupy medicine cabinets— provide convenience and accessibility for patients and caregivers managing one or more chronic conditions, which is a significant part of our population. It is vital to protect these innovation pipelines. “Ending the pill penalty by aligning small molecules with biologics’ 13-year track until price control eligibility, as the President has suggested, would reinvigorate small molecule research and development. The President also rightly affirmed the importance of intellectual property rights to America’s health care ecosystem. “I also commend the President’s call for greater transparency. By confronting these challenges head-on, the President has charted a path that, in no uncertain terms, puts patients first.” ###

  • Partnership to Fight Chronic Disease Urges Policy Makers to Protect Medicaid, Reject Most Favored Nation Pricing Proposal and Prioritize Patient Access

    May 5, 2025 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) today called on Congressional leaders and the Trump Administration to ensure that treatment access for people living with chronic diseases in Medicaid remains a priority across new policies that aim to make America healthy now and in the future. As chronic conditions such as diabetes, cancer, and heart disease affect more than half of all U.S. adults and account for 90% of the nation’s health care costs, we call on decision makers to take patient-focused action to improve health outcomes across America. Any serious Medicaid reform must prioritize prevention, improve access to recommended care, reduce waste, and foster innovation in treatment and care delivery. A healthier America translates to lower health costs, better quality of life, and a stronger, more productive economy. These priorities are particularly critical for Medicaid-covered individuals living with multiple chronic conditions and rural communities facing persistent health disparities.  Special attention must be paid to America’s Medicaid population, which includes about 37 million children, many living with rare diseases, elderly nursing home residents, individuals living with disabilities, and pregnant women. These vulnerable populations face disproportionate barriers to care. Medicaid-enrolled adults have significantly high rates of chronic illness, with nearly one-third living with three or more chronic conditions.  Recent policy proposals that harm Medicaid coverage and access, including a "most favored nation" (MFN) drug pricing model, risk undermining access to the care and medicines on which Medicaid beneficiaries rely for their health. Provider shortages and other access challenges already plague Medicaid and hinder health improvement and cost savings. Tying drug prices to foreign standards, where value assessments often discriminate against people with disabilities and chronic illnesses, could severely limit access to essential treatments, destabilize the very safety net programs that support our most at-risk citizens, and stifle medical innovation. Low provider reimbursement, persistent shortages, and shrinking pharmacy access already make it difficult for Medicaid patients to receive consistent, high-quality care. Any cuts to coverage or reductions in provider payments and reimbursement schemes will only deepen these challenges. With millions more Americans expected to be diagnosed with chronic diseases in the coming years, now is the time to advance policies that support, not hinder, access to treatment, especially for those who need it most. As lawmakers consider efforts to make America healthy again, we urge them to reject proposals that jeopardize coverage and care access for America’s most vulnerable populations. Instead, we need solutions that support access to recommended care and work to advance health innovations that strengthen the nation’s response to chronic disease. ### Media Contact: Jennifer.Burke@fightchronicdisease.org

  • New Poll: Majority of Seniors with Medicare Prescription Drug Coverage Remain Unaware of New Payment Options

    Results Show Interest in the Medicare Prescription Payment Plan Increases as American Seniors Learn More About It April 3, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) today released new polling data showing a majority of seniors with Medicare prescription drug coverage are unaware of the Medicare Prescription Payment Plan, a new program designed to help manage out-of-pocket costs. The findings highlight the need for greater education and outreach to ensure eligible seniors can take advantage of this cost-saving opportunity. The survey, conducted by independent research firms GQR and Public Opinion Strategies, found that just 26% of seniors knew some or a lot about the program, while nearly half (48%) had heard nothing at all. However, once respondents received more information, interest in the program significantly increased. Launched in January 2025, the Medicare Prescription Payment Plan offers seniors with Medicare Part D or Medicare Advantage plans the option to break their out-of-pocket prescription drug expenses into monthly installments to avoid having to make large payments earlier in the year. The new program is a part of a broader series of changes Medicare is making to Part D this year, including an automatic cap on out-of-pocket costs at $2,000 per year. As the survey results demonstrate, greater awareness of the program can lead to increased participation, ensuring more seniors can benefit from this financial flexibility. “These results show that too many seniors are missing out on a program that could help them better manage their prescription drug expenses simply because they don’t know it exists,” said Candace DeMatteis, policy director at the Partnership to Fight Chronic Disease. “When they learn about the Medicare Prescription Payment Plan, they see its value. The low awareness presents the opportunity for policymakers and stakeholders to better communicate how this program can help Americans on Medicare budget for their healthcare expenses more effectively." Additional key findings include: 74% of seniors say they’d heard little to no information about the Medicare Prescription Payment Plan. Seniors say the ability to opt in at any time during the year (76%) and the assurance of no additional costs (75%) are the most convincing reasons to sign up. After receiving information about the program, nearly half (48%) of seniors who report spending more than $1,000 per year on prescription drugs say they would likely use it. 81% of seniors think their Medicare plan or Medicare itself is responsible for making sure they have information about programs like this. “Seniors shouldn’t have to navigate complex healthcare costs without clear information,” GQR senior partner Anna Greenberg said. “By raising awareness and providing accessible information, more Medicare beneficiaries can take advantage of this important cost-saving option.”   “When it comes to their healthcare expenses, seniors want predictability, and the Medicare Prescription Payment Plan can offer exactly that,” Public Opinion Strategies partner Nicole McCleskey said. GQR and Public Opinion Strategies designed and administered this survey of 500 Medicare recipients who have additional prescription drug coverage (either Medicare Part D or Medicare Advantage) from Jan. 27 to Feb. 2, 2025. Most respondents (397) were selected from online opt-in panels, and 103 were contacted by phone to increase coverage of minority and rural respondents.  View the detailed findings here , and visit fightchronicdisease.org  to learn more.

  • Chronic Disease Patients Prioritized in Trump Administration Executive Order

    Successfully addressing the true cost drivers in health care requires policies that recognize the promise of small molecules and stop the perils of PBMs April 16, 2025 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to President Donald Trump’s executive order that, in part, called for fairness in the treatment of both small molecule medicines and biologics in the context of the Medicare Drug Price Negotiation Program: “PFCD emphasizes the significance of the Trump Administration’s most recent executive action, laying down a marker of support to address a critical imbalance created by the Inflation Reduction Act (IRA) and calling for congressional action to fix it.  As the President acknowledged, the so-called “pill penalty” serves as a significant deterrent for the development of the pills, tablets, patches, and other small molecule medicines on which almost anyone living with a chronic disease relies to improve their health. Amending the IRA to equalize the eligibility timeline for price-setting both small molecule and biologic medicines at 13 years is a critical step in improving overall health outcomes and quality of life for the millions of Americans living with one or more chronic conditions, while at the same time ensuring America remains at the forefront of medical innovation. PFCD remains committed to working with Congress and the Administration on these critical health care issues and calling for passage of the Ensuring Pathways to Innovative Cures (EPIC) Act, which would fix the pill penalty. “PFCD also commends the Trump Administration for its recognition of the role Pharmacy Benefit Managers (PBMs) play in raising the costs of prescription drugs for consumers, employers, and insurers, including Medicare. PBMs impede patient access to the medicines their health care providers recommend and put significant risk on medication adherence which is imperative for people living with chronic conditions. We look forward to working with the Trump Administration and Members of Congress to adopt PBM reforms that facilitate patient access, pharmacy choice, and lower costs for all stakeholders.” ###

  • America has both an obesity and health care cost problem.

    Their coexistence is not coincidental. New data application from a recent study further illuminates the relationship between the two major issues, revealing if every American living with obesity hypothetically reduced their body mass index (BMI) by 5%, the cumulative effect would save $68.1 billion in private health insurance spending annually and $21.7 billion in Medicare.   A 10% BMI reduction (i.e. a drop from 30 to 27 BMI; from 40 to 36 BMI, etc.) from every American with obesity, defined as having a 30 BMI or higher, would save $128.3 billion in private insurance and $41.6 billion in Medicare. A 25% BMI reduction annually saves $270 billion and $92.9 billion, respectively. Dr. Ken Thorpe, professor at Emory University and chairman of the Partnership to Fight Chronic Disease, based these findings on figures from his December research study, Estimated Reduction in Health Care Spending Associated With Weight Loss Among Adults . VIDEO: Obe$ity in America: Making Cost Reduction a Reality That study, which used dollars from 2023, explored how lower health care spending is associated with a 5-25% BMI reduction. While BMI is considered an imperfect obesity marker, not accounting for such composition factors as muscle mass, the macro picture paints a clear image of how obesity and health care costs are intertwined. Obesity, itself categorized as a disease, is associated with various chronic diseases. “When reducing body weight and mass, you often reduce blood pressure, cholesterol and blood sugar levels,” Thorpe said. “You alleviate physical stress that can lead to severe complications, including a stroke or heart attack. If we had a different BMI distribution in adults, we would spend less on health care than we do today.” The findings inform a financial lens through which to view personal health. From gym and class memberships, athletic equipment to non-processed groceries, positively associated habits like exercise and nutrition carry a clear, initial financial cost. The same applies for FDA-approved GLP-1 drugs, as the weekly injections have been shown in randomized trials to reduce body mass and lower the likelihood for Type II diabetes and cardiovascular disease, among other benefits. Such dollar signs stare at Americans in plain sight, influencing their daily decision-making. But there is a financial cost, too, for not preventing or mitigating obesity. As Thorpe’s research shows, it’s significant.

  • Biden Administration’s Latest List of Drugs Selected for Medicare Pricing Exacerbates Access and Innovation Risks to People Living with Cancers & Other Chronic Diseases

    January 17, 2025 (WASHINGTON, D.C.) Today, the Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Biden Administration’s announcement of 15 new drugs selected for Medicare price negotiations under the Inflation Reduction Act:  "Tens of millions of Americans living with chronic diseases like diabetes, cancer, and high blood pressure rely on prescription drugs to manage their conditions and avert costly and life-threatening health emergencies. Improving access to medications to treat these conditions is critical, but government pricing has the opposite effect. We encourage the incoming Administration and new Congress to revisit the flawed program and pursue reforms that preserve access and promote innovation for people living with chronic disease.   “Each of the drugs CMS selected for pricing are small molecule medicines that are not only essential to the treatment of many chronic diseases but also are favored by seniors for their ease of use and accessibility. IRA provisions disadvantage these medicines in favor of medicines that require administration by a healthcare provider, which greatly hinders access in rural and other underserved areas. Patient advocates have repeatedly called for reforms like the bipartisan EPIC Act  to preserve access to small molecule medicines. CMS’s latest list makes the EPIC Act and other reforms even more urgent.  “CMS also continues to stretch its overly broad definition of “qualifying single source drug” to treat distinct products with different medical uses and subject to individual FDA approvals as a single selected drug. This action ignores clinical realities, the research and development efforts involved, and severely undermines the development of new products that address unmet medical needs.  “Despite concerns raised by patients and providers, CMS has refused to require protections for patient access including increased prior authorization requirements that risk patient health and burden providers. Along with significant premium increases and loss of Part D plan options, these flaws provide ample justification for the incoming Administration to delay implementation and allow time to revisit and reform the program.  "Moreover, government price setting policies are not addressing the true cost drivers in our health care system. Just this week, the Federal Trade Commission found that PBMs pocketed more than 7 billion dollars by inflating drug prices from 2017-2022 alone. Ignoring the role that insurers and pharmacy benefit managers play in increasing costs at the pharmacy counter isn’t going to deliver any savings to the people who need it.  "Currently, more than half of Medicare beneficiaries are managing three or more chronic conditions, and as Medicare enrollment continues to rise, so do the associated costs. Rather than attempting to curb these expenses with price controls, policymakers must work to better address the rise in chronic disease by elevating prevention and eliminating increasing barriers to care and treatment.  "There is great urgency to reform IRA policies that ignore the real needs of Medicare beneficiaries. Unresolved concerns over the significant harm to patient access and clear evidence of R&D funding shifting away from small molecule medicines highlight the immediate need to revisit and reform the IRA’s drug pricing program before allowing it to continue. PFCD stands ready to advance policies that realistically account for the true burden of chronic disease in our country and genuinely support effective chronic disease management aimed at better overall health outcomes in the U.S."

  • NEW ANALYSIS SHOWS WEIGHT LOSS SAVES EMPLOYERS AND MEDICARE HEALTH CARE COSTS

    Modest weight loss among adults with obesity cuts health care spending by 15%, reduces costs across comorbidities December 5, 2024 (Washington, D.C.)  Obesity is quickly rising to the top of the list of chronic conditions in the U.S. with more than 40 percent of adults having obesity, with the highest prevalence seen among adults aged 40-59 years – prime working years. [1] Obesity also increases the risk of developing a host of other chronic conditions including diabetes, cardiovascular disease, and many cancers. Addressing obesity by promoting weight loss, accordingly, should reduce costs not only related to obesity but also these comorbid conditions. Recent research by Emory University Professor and Partnership to Fight Chronic Disease (PFCD)  Chair Ken Thorpe published today in JAMA Network Open  – Estimated Reduction in Health Care Spending Associated With Weight Loss Among Adults – highlights the potential savings resulting from modest to moderate weight loss by adults with obesity, including savings by comorbid condition, represented by reduced health care spending among U.S. adults with employer-sponsored insurance or Medicare. Key findings from the research include: Economic Burden of Obesity : In 2023, obesity cost employers and employees $400 billion, with health care costs accounting for less than half that total. Obesity-related higher medical costs alone added $1,514 per person. [2] This new research shows that modest to moderate weight loss would significantly reduce those costs: For individuals with employer-sponsored insurance: A 5% weight loss reduced health care spending by $670 or 8% per person annually. A 25% weight loss reduced spending by $2,849 annually or 34%. For weight loss of 5-20%, individuals with the following comorbidities would realize the greatest reductions in annual health care spending: Obesity and diabetes - $1,840-$5,821 Obesity and arthritis - $1,917-$6,143 Obesity and chronic back problems - $1,422-$4,729 Medicare stands to save even more: A 5% weight loss reduced spending by $1,262 (7%) per person annually. A 25% weight loss reduced spending by $5,442 (31%) per person annually. Lifestyle Intervention Implications : Lifestyle programs that promote healthy eating and exercise coupled with evidence-based treatment interventions (e.g., bariatric surgery or novel weight-loss medications/GLP-1 agonists) are effective tools but may face coverage restrictions that limit access. Expanding access to evidence-based treatments for obesity could yield substantial health care savings. These findings highlight the significant potential for achievable weight loss among adults with obesity to reduce health care costs and the economic burden of disease, particularly for those living with multiple chronic conditions or high BMI levels. This is especially promising relative to last week’s proposal by the Centers for Medicare & Medicaid Services to cover anti-obesity medicines under Medicare Part D and Medicaid when used to treat obesity. If finalized, this broad new coverage would have a profound impact on the ability of Americans to access these novel medications that could significantly reduce obesity-related health care spending and improve overall health. “We must address obesity as the disease it is by focusing on prevention and treatment that empowers people to lose weight and maintain a healthy weight while improving their health. Reducing obesity lowers costs across several chronic conditions and should be a priority focus for employers, Medicare and other payors moving forward,” urged Thorpe.  For the full research and more information on efforts to address obesity: www.fightchronicdisease.org/obesity . https://www.businesswire.com/news/home/20241205473135/en/New-Analysis-Shows-Weight-Loss-Saves-Employers-and-Medicare-Health-Care-Costs [1]   https://www.cdc.gov/nchs/products/databriefs/db508.htm [2]   https://ehdinsurance.com/report-obesity-cost-employers-and-employees-ove...$1%2C514%20in%20higher%20medical%20costs,$2%2C427%20in%20higher%20presenteeism%20costs

Stay informed about PFCD, sign up for updates:

Thank you. Your email has been submitted.

By providing my mobile number I consent to receive informational text messages from Partnership to Fight Chronic Disease. Message frequency may vary. Msg & Data rates may apply. Donations will not be solicited. Text STOP to opt-out. Text HELP for help. For additional information, please see our Terms & Conditions and Privacy Policies. Mobile and opt-in data will not be shared with third parties.

© Copyright 2025. Partnership to Fight Chronic Disease

bottom of page